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Chapter1 
GENERAl INTRODUCTION 
1.1 Circulating and local renin-angiotensin systems 
Circulating renin-angiotensin system; the Classic concept. 
Until a decade ago the renin angiotensin system (RAS) was considered to be a classic 
endocrine negative feedback system regulating blood pressure and sodium-potassium 
homeostasis (1). The aspartic protease, renin, the initiating enzyme of the RAS-
cascade, is secreted by the juxta-glomerular cells of the kidney, in response to a variety 
of stimuli, such as a drop of the transmural pressure gradient across the juxtaglomerular 
cells, reduced delivery of sodium to the distal tubular macula densa sites, and activation 
of beta - adrenoreceptors located in the juxtaglomerular cells. 
Renin released by the kidney circulates in plasma and cleaves angiotensinogen, 
produced by the liver, thereby generating the biologically inactive decapeptide 
angiotensin I (Ang 1). Angiotensin I in turn is converted in plasma into the octapeptide 
angiotensin II (Ang II) that is biologically highly active, by angiotensin converting 
enzyme, a dipeptidyl aminopeptidase whose concentration is especially high in the 
pulmonary vascular endothelium. Ang II is conveyed by arterial blood to the peripheral 
tissues, where it exerts its effects by interaction with specific Ang II receptors. 
Ang II increases peripheral vascular resitance through powerful constrictor effects on 
vascular smooth muscle. Ang II reduces renal sodium excretion by acting directly on 
renal blood vessels and on renal tubular cells and by acting indirectly via increased 
aldosterone secretion from the adrenals (Figure 1). 
Circulating versus local renin-angiotensin systems; the new concept 
The classic concept of the circulating RAS, the activity of which depends on the 
regulated secretion of renin from the kidney, has been extended in the last years. An 
increasing number of studies has now demonstrated the existence of local tissue 
angiotensin generating systems which may operate, at least in part, independently of the 
circulating RAS (2,3). 
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According to one hypothesis, the primary function of the circulating RAS is not the 
systemic delivery of Ang II to tissues, but rather the delivery of renin and possible also 
angiotensinogento tissues; A main fraction of Ang I and All is generated locally at tiSsue 
sites by the action of plasma-derived renin (or perhaps prorenin) originating from the 
kidney on locally synthesized or plasma-derived angiotensinogen. The locally formed 
Ang I may then be converted in situ to Ang II or may enter the circulation and converted 
at the luminal site of the endothelial cells lining the blood vessels (4-6, Figure 2). 
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The detection of mRNA for renin and angiotensinogen in some tissues is strong evidence 
for local synthesis of these components in these tissues. The existence of a complete 
RAS system in the kidney has been well documented( 7,8). Ang II formation in extrarenal 
RAS tissues has been demonstrated for instance in the adrenals (9,10), the pituitary 
(9,10), the brain (11), testis (10), ovary (11,12) and in vasculartissue(13-17). 
Most, if not all, renin in circulating plasma originates from the kidney, but a major 
fraction of prorenin in plasma is of extrarenal origin. It has been shown that testis and 
ovary can indeed secrete prorenin into the cicrculation (18-20). 
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Figure 2: Circulating renin-angiotensin system versus local renin-angiotensin system: 
interactions and possible angiotensin generation sites. 
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Prorenin: 
In the kidney, prorenin is synthesized in the juxtaglomerular cells, where it is converted 
to renin. The kidney secretes both renin and prorenin into the circulation. 
Since the initial identification of inactive renin in amniotic fluid by Lumbers (21) in 1971, 
much progress has been made in understanding the relationship between prorenin and 
renin. This progress was possible partly as a result of the purification of native human 
renin with the generation of antibodies against renin (22·24) and cloning of the human 
renin gene sequences. These events made it possible to study renin gene expression 
and to produce recombinant prorenin and renin and to provide knowledge of their 
complete amino acid sequences (25-28). 
Cellular processing and secretion of prorenin and renin in the juxtaglomerular cells 
can follow two pathways: the regulated pathway or the constitutive pathway. 
Preprorenin is the primary translation product of renin messenger RNA (25-28). 
The 23-aminoacid signal, or "pre'' sequence, directs insertion of the protein into the 
lumen of the rough endoplasmatic reticulum and this is associated with rapid cleavage 
to form prorenin (29,30). In this inactive state, prorenintraversesthe rough endoplasmatic 
reticulum and Golgi apparatus where it is glycosylated. The extent of glycosylation is 
variable, both in the renin produced by the kidney and that produced by extrarenal 
sources (28,31 ,32). 
From the Golgi apparatus, prorenin can be sorted to one of three compartments, which 
include two secretory pathways (regulated and constitutive) and the Iysosomes. 
Prorenin has been demonstated to bind to mannose 6-phosphate receptors, which 
appear to facilitate its entry into the lysosomal compartment, where it is degraded to renin 
(33). The percent of cellular renin that enters this compartment is unknowm, but probably 
small (approximately 5%) (33). 
Prorenin can also be sorted to the regulated pathway, in which prorenin is stored in 
secretory granules. Active renin is the primary product of the regulated secretory 
pathway (34,35). Prorenin-to-renin conversion appears to occur in the secretory granule 
and release of renin from the granules occurs after stimulation by a secretagogue. 
Several different proteases have been implicated as potential processing enzymes, for 
instance in the kidney a thiol protease resembling cathepsin B (37). This proccessing 
enzyme cleaves the amino terminal43-amino acid prosegment, which allows exposure 
of the active site of renin. 
Prorenin can also enter the constitutive pathway, in which prorenin is the secretory 
product (34,35). This pathway is not regulated acutely and delivers prohormone to the 
cell surface at a constant rate (37). 
Two human tissues have been identified that primarily secrete prorenin; an ovarian 
leiomyosarcoma and the decidua of pregnant women (18,38). 
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Regulation of pro renin ; observations in humans 
It is unknown which factors detennine whether the Golgi apparatus sorts prorenin to 
either the regulated or the constitutive pathway (39). 
The kidney releases both renin and prorenin. Acute stimulation of the juxtaglomerular 
cells, for instance exercise, isoproterenol infusion or a first dose frusemide leads to a 
prompt rise of plasma renin with no change in plasma prorenin (40,41). Chronic 
stimulation, for instance sodium restriction, captopril treatment leads to a rise of both 
plasma renin and prorenin. 
The stronger the stimulus the higher the percentage contribution of renin to the level 
of total renin (pro renin plus renin) in plasma. The proportion of the total amount of 
circulating prorenin that is secreted by the kidneys is probably also increased under 
these circumstances (40-44). In other words, acute modulation of the juxtaglomerular 
cells leads to alterations in the renin release from the regulated secretory pathway with 
little effect on the constitutive pathway, although marked stimulation of the regulated 
pathway appears to result in decreased constitutive release of prohonnone and chronic 
modulations leads to both renal renin release and prorenin release from the constitutive 
secretory pathway. The nature of the mechanisms regulating these relationships 
between prorenin and renin secretion is unknown. 
Normal human plasma contains prorenin in a concentration about ten times higher 
than that of active renin. Plasma of nephrectomized patients contains little or no renin 
but the concentration of prorenin is sometimes as high as in normal individuals (45,46). 
In average the prorenin concentration in nephrectomized patients is about one third of 
that in controls. Thus, about one third of the plasma prorenin in normal subjects appears 
to be of extrarenal origin. 
Extrarenal sources of plasma prorenin; observations in humans. 
In pregnant women the plasma concentrations of both renin and prorenin are increased 
but, in contrast with what one sees during chronic stimulation of the release of renin by 
the kidneys, the percent increase in plasma prorenin is much greater. This is already the 
case in the first trimester of pregnancy (47,48). There is now good evidence that the 
ovary is the main source of this increase in plasma prorenin. Plasma prorenin is about 
two times higher in the luteal phase of the menstrual cycle than in the follicular phase. 
An increase in prorenin at the time of ovulation or shortly thereafter comparable to the 
increase in pregnancy has been reported in women who were treated with gonadotropins 
because of an in vitro fertilization program (49,50). The prorenin concentration in the 
ovarian follicular fluid of these women is about 40 times higher than the concentration 
in plasma (51 ,52). 
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In a woman without functioning ovaries, who became pregnant aflertransfer of a donated 
fertilized oocyte, pre-pregnancy plasma levels of prorenin and renin were normal and 
renin rose two-fold during pregnancy in this patient as it does in normal pregnant women. 
Prorenin, however, did not show the normal rise in the first eight weeks. In addition 
plasma prorenin remained low throughout pregnancy( 53). Because of these findings it 
seems likely that the ovary is an important source of the elevated plasma prorenin in 
pregnancy, not only in the first trimester but also in the last. 
Renin mRNA expression suggests that the decidua is the major source of renin in the 
uterus and placenta. Renin gene expression was not detected in amnion, basal plate 
chorion, myometrium or the placental villi (18). 
The lack of renin gene expression, but positive immunostaining in chorion, suggests 
that this menbrane does not produce prorenin but is capable of taking prorenin that is 
synthesized by the decidua and transporting it into the amniotic fluid, which is known 
to contain high quantities of prorenin. 
It is not known whether prorenin is involved in the reproductive physiology, either 
locally or systemically. 
Another well known source of plasma prorenin are the renin-secreting tumors. 
Most tumors arise from the kidney (nephroblastoma, juxtaglomerular cell tumor or 
reninoma), are malignant, and are associated with hypertension and hypokalemia. 
They secrete both renin and prorenin, but mainly prorenin into the circulation (54-56). A 
series of fifteen extrarenal renin-secreting tumors has been reported; 14 of these were 
in women, and seven were located in the reproductive tract (38). All tumors were 
malignant. Some tumors were highly vascularized, for instance in the case of an 
angiolymphoid hyperplasia with eosinophilia, glioblastoma multiforme, haeman-
giopericytoma and alveolar soft-part sarcoma and a close correlation and the degree of 
neovascularization has been repoted (57,58). 
In conclusion, it seems that extrarenal RAS systems such as in the ovary and renin-
secreting tumors have in common that they are located in highly vascularized tissues 
and that they secrete mainly prorenin, via the constitutive pathway, into the extra-cellular 
space. Whether the prorenin secreted by this pathway is subsequently activated in situ 
or is taken up by other tissues and then activated, remains to be determined. 
Functions of angiotensin II 
Ang II is, at least in humans, the most important biologically active endproduct of the 
RAS. Apart from its well-known role in blood pressure regulation Ang II has mitogenic 
and angiogenic properties. Ang II has beyond its direct vasoconstrictive and aldosterone 
synthesis-promoting effects to control adequate capillary perfusion, some growth 
modulating effects. Ang II appears to be a growth regulator in the kidney. It binds to 
specific cell surface receptors present on a number of different renal cell types including 
mesangial, vascular smooth muscle, tubular and interstitial cells, and activates many 
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of the intracellular signalling pathways associated with cell growth in the kidney (59,60). 
Ang II has been shown to stimulate DNA and protein synthesis in cardiovascular tissues 
(61) and induces hyperthrophy without cellular proliferation in cultured aortic smooth 
muscle cells (62). Whether All stimulates vascular smooth muscle cell proliferation, 
directly or via potentiating other growth factors (EGF, PDGF) is still under discussion 
(59,63). 
Anyway, after renal ischaemia Ang II restores blood flow to tissues below an aortic 
ligature by stimulating the development of collateral circulation (64). Furthermore, 
implantation of Ang II in the avascular rabbit cornea facilitated not only the activation of 
preexisting collateral pathways but also new vessel formation (65). 
In the ovary luteinization of the follicle takes place following ovulation. This coincides 
with rapid and extensive neovascularization of the developing corpus luteum. 
It is possible that local generation of prorenin and formation of Ang II are involved in 
neovascularization of the developing corpus luteum. 
Captopril, an angiotensin converting enzyme inhibitor, not only lowered blood pressure, 
but was also more effective than hydralazine and propanolol in preventing increaments 
in aortic smooth muscle content and medial smooth musle content weight during 
development of hypertension in the spontaneously hypertensive rat (66). 
Recently Wang et al (67) have shown that captopril treatment in one-kidney, one-clip 
hypertensive and normotensive rats resulted in reduction in cross-sectional wall area 
of aortas and arterioles in both normotensive and hypertensive rats, as well as a 
reduction in the number of small arterioles. 
Uptake of renin or pro renin by vascular tissue 
Labeled Ang I infusion studies showed that the major fraction of Ang I and Ang II in 
circulating plasma is produced locally at the tissue sites rather than in circulating 
plasma (68,69). The Ang I production rates in the various tissues correlated with PRA, 
suggesting that most oflhe renin responsible for local ANG I production is kidney-derived 
rather than dependent on in situ synthesized renin. 
Other indirect evidence of vascular uptake of renin is based on experiments in rats after 
bilateral nephrectomy (70-72). Direct evidence of vascular renin uptake was shown by 
demonstrating renin uptake in aortictissueafterrenin injection in bilaterally nephrectomized 
rats (73,74). Infusion of recombinant human prorenin in rhesus monkeys shows direct 
evidence for uptake of prorenin (75) and demonstrated thatthe infused prorenin had none 
of the effects of renin and that circulating prorenin is notthe precursorforcirculating renin 
(76). 
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Possible physiological role of prorenin 
The only well-established role for prorenin is that it is a mandatory intracellular precursor 
for the synthesis of active renin. 
In vivo there is no evidence for activation of prorenin in plasma. this is illustrated by the 
complete absence of renin activity in nephrectomized human subjects (77). However, 
prorenin can be activated in vitro by limited proteolysis with trypsin or other proteases, 
this results in cleavage of the prosequence and the irreversible formation of active 
renin (78). Interestingly, prorenin can also be activated by acid or cold temperature 
which results in a reversible activation (79,80). 
Prorenin can be reversibly activated in vitro when acidified to pH 3.3 and only to be 
deactivated when incubated at neutral pH and 37°C and when prorenin is chilled to ooc 
it develops renin like activity that disappears when the sample is warmed to 37"C. 
It has been suggested that acidification or freezing causes the prorenin molecule to 
physcally unfold its prosegment (open position) and thus to expose its active site, while 
refolding and shielding of the active site takes place upon neutralization or wanming 
(81, Figure 3 ). 
3BAsp 22GAsp 
PRORENIN 
'CLOSED' 
POSITION 
3BAsp 
Figure 3: Hypothetical activation of prorenin by unfolding the prosegment. 
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This observation made Sealy et alto speculate that conditions may exist in target organs 
in vivo that favor the "open" fonm of prorenin (figure 3). They hypothesised that prorenin 
can bind to specific receptors which activate prorenin without cleavage ofthe prosegment. 
If the prorenin receptor were located near converting enzyme and angiotensin II receptor, 
in the presence of angiotensinogen, the activated prorenin could cleave angiotensin I 
from angiotensinogen which in turn could be activated by converting enzyme to 
angiotensin II (81 ). 
After infusion of human prorenin into monkeys high concentrations of prorenin or renin 
protein (which could not be distinguished) were localized immunohistochemically in the 
glomerular region of the afferent arteriole where very high Ang II concentrations were 
detected with immunohistochemistry (82). In their model prorenin is to generate localized 
high concentrations of Ang II causing regional vasodilation by rendering tissues 
insensitive (tachyphylactic) to the vasoconstrictor effect of circulating Ang II or by 
releasing vasodilator substances (82,83). 
In animals and humans, organs with high rates of blood flow- kidney, eye, ovary, 
pregnant uterus and placenta- all produce high concentrations of proren·,n. An abnonmal 
plasma prorenin could be the cause of the renal and retinal hyperperfusion that occurs 
in diabetes mellitus and is thought to predispose people to the development of 
microvascular disease. (84). 
1.2 The renin-angiotensin system and diabetes mellitus 
In 1972 Christlieb et al wereth~ first who reported upon the RAAS and diabetes mellitus. 
They were interested in factors involved in initiating and sustaining the hypertension 
which frequently accompanies both type I and type II diabetes mellitus (85,86). 
The renin-angiotensin system in ketoacidosis 
Christlieb et al began their humun studies in patients with uncontrolled diabetes.ln 
patients with ketoacidosis rather high plasma levels of renin activity (PRA) and 
aldosterone were found, suggesting a state of secondary hyperaldosteronism. Shortly 
after treatment (4-48 hours) with insulin, PRA levels decreased to nonmal (85). Several 
other groups confirmed these observations (87-89). The plasma levels of angiotensin II 
(Ang II) are also high in most ketotic patients (90). The high renin levels have been 
attributed mainly to fluid volume depletion and possibly also to a direct effect of 
metabolic acidosis on renin release (88). 
Circulating catecholamines, especially norepinephrine, are elevated in established 
ketoacidosis, and return to nonmal after metabolic control (90). 
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The renin-angiotensin system in uncontrolled nonketotic diabetes 
In non-ketotic diabetes PRA has been variously reported to be high, normal or low 
(91-96). This variability may perhaps be explained by differences in the severity of 
metabolic disease and by differences in the type of diabetes (type I and type II), and 
by the presence or absence of complications ( nephropathy, autonomic neuropathy). 
With improved control the levels of PRA, Ang II returned to normal (96). 
Basal levels of catecholamines are unchanged by poorly controlled diabetes; when 
metabolic control was improved supine and upright plasma norepinephrine concentrations 
did not change (97,98). 
Christensen et al (99) measured PRA, Ang II, glomerular filtration rate (GFR) and renal 
plasma flow (ERPF) in newly diagnosed type I diabetic (IDDM) patients before and during 
initial insulin treatment. 
Both GFR and ERPF were elevated at the start and fell significantly after 8 days of 
insulin treatment. PRA an renin substrate (angiotensinogen) were normal at the start 
and remained unchanged during treatment. Plasma Ang II was low initially and also 
remained unchanged. 
The renin-angiotensin system in diabetes with and without microvascular complications 
Christlieb et al (92) extended their research to diabetics with or without diabetic 
complications. In patients without clinical evidence of microvascular complications the 
RAS appeared to function normally, as jugded from the fact that PRA were normal and 
PRA responded normally to stimuli of sodium depletion and upright posture . 
These results were confirmed by other authors (100-104). On the other hand, an 
increased vasopressor responsiveness to exogenous Ang II was found in normotensive, 
normoalbuminuric patients without retinopathy (1 05). 
Again, Christlieb et al (92,105) were the first to report about low PRA levels and a 
blunted response to stimuli in diabetic patients with nephropathy and/or severe 
orthostatic hypotension. Suppression of the RAS when diabetes is complicated with 
clinical nephropathy and autonomic neuropathy has been reported by several other 
authors (106-109). 
In patients with retinopathy as the only obvious diabetic complication normal basal PRA 
and normal responsiveness of PRA were described by Christlieb et al (110). In such 
patients the vascular reactivity to both Ang II and norepinephrine was found to be normal 
and diastolic blood pressure was higher in the group with retinopathy. 
Druryet al (1 02-1 04) also reported on higher PRA (supine and erect) in type I diabetics 
with proliferative retinopathy as compared to diabetics without complications and to 
normal persons, matched for age, sex and bodyweight. Patients with proliferative 
diabetic retinopathy (PDR) had higher blood pressures (both systolic and diastolic) and 
worse metabolic control, and the inverse relationship between PRA and blood pressure 
and sodium excretion which was seen in normal controls and diabetics without 
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complications, was not apparent in the group with proliferative retinopathy (102-104). 
It is difficult to compare the results published by different groups, because of 
heterogenity of the study populations, the different definitions of nephropathy.ln addi-
tion, earlier studies could not differentiate between incipient or overt proteinuria. Finally, 
control groups were sometimes used withthout adequate matching and last but not least 
different methods were used for measuring the components of the RAS. 
The plasma level of renin in most studies was measured as PRA with an enzyme kinetic 
assay. Results of this assay are affected by assay conditions, such as pH, the use of 
angiotensinase inhibitors, and the concentration of renin substrate in the plasma. 
Diabetic patients without clinical evidence of microvascular disease have a normally 
acting RAS; their plasma levels of PRA, renin and aldosterone seem to be normal under 
basal and stimulated conditions. Patients with clinical evidence of complications seem 
to have a depressed RAS; the plasma levels of PRA, Ang II and aldosterone are all low 
(111-113). 
Mechanisms of hyporeninemia in diabetes mellitus 
Possible mechanism for this hyporenemia in complicated diabetes are (92): 
1) expanded blood volume due to sodium retention or plasma hyperosmolarity 
resulting from hyperglycaemia, 2) destruction ofjuxtaglomerularcells due to nephropathy, 
3) decreased activity of the the sympathetic nervous system, 4) defective renin 
synthesis due to insulin deficiency and 5) decreased renin substrate. 
Expanded blood volume. 
There is evidence for sodium retention in diabetes mellitus. 
It has been observed both in type I or type II diabetes regardless of patients age, sex, 
presence or absence of proteinuria, retinopathy and peripheral neuropathy (116). 
Moreover sodium retention was evident in both norma- or hypertensive subjects. Blood 
and plasma volumes were normal in normotensive diabetics, and reduced in hypertensive 
diabetics (97,114-116). 
Feldt-Rasmussen et al (113) measured the plasma renin concentration and the 
concentration of Ang II and aldosterone in patients with normoalbuminuria, 
microalbuminuria and overt nephropathy in relation to exchangeable sodium and blood 
volumes. They found normal renin levels and suppressed angiotensin II and aldosterone 
levels regardless of the presence or absence of albuminuria. The plasma levels of 
norepinephrine and epinephrine were also reduced in patients with albuminuria. 
Exchangeable sodium was elevated in most diabetics, especially in patients with overt 
nephropathy. Blood and plasma volumes were normal. 
The increase in exchangeable sodium was accompanied with an increased extracellular 
volume. Blood pressure was significantly correlated with exchangeable sodium in the 
group with microalbuminuria. 
19 
There is substantial evidence that sodium retention in diabetes is mainly due to en-
hanced tubular reabsorption of sodium (117). As mechanisms underlying the sodium 
retention have been proposed an increased glucose- coupled tubular reabsorption of 
sodium (118) or an insulin induced increased tubular reabsorption (119, 120). The 
observed increased vascular reactivity to Ang II and norepinephrine might be a 
physiological response to sodium retention. Sodium retention is likely to play a role in 
the blood pressure rise observed at the very early stages of diabetic nephropathy. 
Hyperfiltration as observed in the early stages is probably a compensating mechanism 
for sodium retention , so that blood pressure is kept within normal limits. 
Destruction of juxtaglomerular cells. 
Hyalinization of the afferent glomerular arteriole offers another explanation for renin 
suppression in longstanding diabetes mellitus. The process is usually segmental and is 
unlikely to explain renin supression in patients with short duration of their diabetes. 
Decreased activity ofthe sympathetic nervous system. 
Autonomic diabetic neuropathy with secondary diminshed activity of the sympathetic 
nervous system may also affect renin release (106,107). Low circulating levels of 
catecholamines and an increased pressor response to norepinephrine have been 
observed (121-124). It is well established that renin secretion is under control of beta ad-
renoceptorstimulation. However, patients with othostatic hypotension due to autonomic 
neuropathy had normal PRA both supine and upright (105). 
Defective renin synthesis. 
Originally Christlieb et al (92) considered insulin-deficiency as a cause of a defect in 
renin synthesis. However, rather high PRA levels were found in diabetic ketoacidosis, 
a clear state of insulin-dependency. Defective renin synthesis as a explanation for low 
PRA was suggested in 1974 by Day et al (125) after the discovery of large amounts of 
big renin, an inactive form of renin, in plasma of patients with diabetes mellitus and 
proteinuria. Deleiva et al (126) describes in 1976 two diabetics with nephropathy and 
hyporenemic hypoaldosteronism and high levels of inactive renin. It was suggested that 
high levels of inactive renin represented a defect in the conversion of inactive renin to 
active renin, a defect caused by renal diabetic damage. A near complete block in renin 
production could result in very low plasma renin accompanied by high prorenin and low 
aldosterone. 
The inactive renin of kidneys and plasma, later on, tumed out to be prorenin, the 
precursor of mature renin, derived from preprorenin (127). 
From now on attention was directed from renin to prorenin and the prorenin-renin 
conversion. 
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Decreased renin substrate. 
There is no evidence for a renin substrate deficiency according to Feldt-Rasmussen in 
type I diabetes with albuminuria or overt nephropathy (113). 
Prorenin and diabetes mellitus 
In their initial survey, Day et al discovered that the plasma of patients with diabetes and 
proteinuria contained large amounts of inactive renin. Bryer-Ash (128) et al showed 
that prorenin levels rose to unusualy high levels in diabetic patients with albuminuria 
after intravenous administration of the diuretic furosemide. 
The largest increments occurred in patients whose active renin did not rise to the usual 
level after furosemide treatment. In normal subjects the increase in prorenin was very 
small after furosemide regardless of the PRA response. 
Similar responses of inactive renin in diabetics after furosemide were reported by 
Manchandia et al (129). 
The kidneys are the most likely source of the increased furosemide-stimulated rise in 
plasma prorenin in the diabetic patients (130). 
Elevated prorenin in diabetic nephropathy may reflect a diminished conversion of 
prorenin to renin. in patients with retinopathy but without overt proteinuria , however , 
Bryer-Ash et al (131) reported on significantly raised plasma prorenin levels, suggesting 
a relation between elevated plasma prorenin and retinopathy, a relation that is partly 
independent of nephropathy. 
Luetscher et al (132) examined the relation between prorenin and the presence of 
diabetic microvascular complications. Plasma renin and inactive renin (prorenin) was 
measured in 235 diabetic patients (type I and type II) and in 90 controls. In the controls 
there was a significant relation between plasma prorenin and age (r=0.30, p<0.001 ). 
Among type I diabetics plasma prorenin was significantly correlated with age (r=0.26, 
p<0.01), duration of diabetes (r=0.36, p<0.01), and the presence of microvascular 
complications (retinopathy and/or albuminuria of more than 50 mg/). 
In type II diabetes the correlation between prorenin and age did not reach statistical 
significance, as it was for type I, however plasma prorenin was correlated with duration 
of diabetes ( r=0.36, 0.01) and also with the presence of diabetic complications. 
Figure 4 shows the relation between plasma pro renin and the presence of microvascular 
complications. The highest values of plasma prorenin were found in the patients with 
albuminuria. Plasma renin levels did not differ in controls and patients with or without 
diabetic complications. 
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Figure 4: Plasma prorenin in relation to ageandthe presence of microvascular complications in type I (left) 
and type II (right) diabetes. Patients without complications are represented bysquaresandthose 
with complications (retinopathy, neuropathy or albuminuria) by triangles. Dashed lines delimit 
95 percent of values in controls. Prorenin is expressed as nanograms angiotensin! per milliliter 
of plasma per hour. From Luetscher et al. (132). 
It was proposed that the plasma level of prorenin may be used as a marker of 
microvascular comlpications. Luetscher suggested that the excess of plasma prorenin 
is secreted by kidneys. 
The kidneys might have a limited ability to process prorenin to active renin. However, 
a extra-renal source of the elevated plasma prorenin was not excluded by Luetscher. 
The reason for this inability, according to Luetscher et al, might be an alteration in the 
intracellular renin biosynthesis, for instance non-enzymatic glycosylation of one of the 
prorenin- processing enzymes. Cathepsin B, a kidney protease that can convert in active 
renin to active renin, becomes inactive after incubation with high concentrations of 
glucose (133-135). 
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Loss of adrenergic stimulation, as is seen with diabetic autonomic neuropathy, may lead 
to decreased secretion of renin by the juxtaglomerular cells and it has been postulated 
by two groups of investigators (136, 137) that a compensatory increase in the synthesis 
and secretion of prorenin by these cells is the cause of the increase of porrenin in 
diabetes mellitus. 
Whether increased plasma prorenin is related to kidney involvement or visa versa is 
an important question. The two processes, one leading to albuminuria, and the other to 
increased plasma prorenin, maybe independent, although they seem to converge as the 
renal laesion progresses. Prospective studies were needed to solve this problem. 
Luetscher et al (138) investigated the relation between plasma prorenin and micro-
albuminuria in IDDM and NIDDM patients. Both in IDDM and NIDDM normotensive 
patients plasma prorenin was correlated with increasing levels of albuminuria. This 
relation was not consistently present in the hypertensive subjects, in three of nine 
hypertensive patients with gross albuminuria the plasma prorenin value was in the 
normal range. 
Other data reported by Luetscher (139) show that in type II diabetics with hypertension 
the association between microvascular complications and prorenin is less reliable, even 
when they excluded patients with antihypertensive drugs which could effect plasma 
prorenin level. 
Amemiya et al (140) reported higher levels of prorenin along with the progress of the 
degree of albuminuria in IDDM patients. The ratio of active renin and total renin was even 
lower in the normoalbuminuric patients as compaired with non-diabetic controls, 
suggesting an altered synthesis of renin with lower conversion rate of prorenin to active 
one as earty as in the normoalbuminuric stage. 
Prospective data reported by Wilson et al (141) suggest that in adolescent diabetics 
a rise of prorenin even precedes the development of microvascular complications. 
Among the patients who had had diabetes for more than four years, the mean plasma 
prorenin activity in those (n;7), in whom retinopathy or overt albuminuria developed was 
significantly higher 18 months before the complication appeared than in those (n;2Q) in 
whom no complication appeared during a similar period of observation. 
They used, however, the presence of overt albuminuria in stead of microalbuminuria as 
a sign of microvascular involvement. Patients with either intermittent or continious 
microalbuminuria had higher levels of plasma prorenin than patients without 
microalbuminuria, but the difference was not statistically significant, only overt 
microalbuminuria was significantly related to plasma prorenin. Their data also suggest 
retinopathy being a more importantfactor related to plasma pro renin than intermittent and 
continious microalbuminulia. 
In Figure 5 the incidence of microangiopathy related to plasma prorenin in 34 patients 
with previously uncomplicated diabetes during 12-54 months of follow-up is shown. 
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Figure 5: Incidence of microangiopathy (retinopathy or overt albuminuria) in 34 patients wrth previously 
uncomplicated type I diabetes mell~us during 12-54 month offollow-up. The dashed line denotes 
patients whose plasma prorenin activity was consistently within the normal range; a complication 
developed in only one of the 21 patients. The solid line denotes patients whose plasma prorenin 
activity exceeded the upper limit of normal (11.5 ng angiotensin 1/l.s ); a new complication 
developed in 8 ofthe 14 patients. From Wilson and Luetscher (141). 
In conclusion, in longstanding diabetes mellitus complicated by microvascular disease, 
the plasma level of prorenin is often 2-3times normal, whereas renin is below the normal 
range. The cause of the elevated plasma pro renin is unknown. There are two main 
possibilities, first an increase in the renal or extrarenal synthesis of prorenin and 
secondly a reduced renal or extrarenal clearance of prorenin. 
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1.3 Aim of the thesis 
The questions we hoped to answer by the studies in this thesis are: 
1. Is an increased circulating level of prorenin indeed related to the presence of 
microvascular disease in diabetes mellitus and, if so, with which type of complication 
(retinopathy, nephropathy, or neuropathy) is it associated ? . 
2. What is the source of the increased circulating prorenin in longstanding diabetes 
mellitus?. 
3. Is the RAS, local and/or systemic, involved in the pathogenesis of 
diabetic microvascular complications?. 
4. Is it possible to use plasma prorenin measurement as an early marker of 
microvascular disease, especially in respect to microalbuminuria?. 
References: 
1. Re RN. Cellular biology of the renin-angiotensin systems. 
Arch lntemMed.1 984;44:2037-2041. 
2. Frohlich ED, Iwata T, Sasaki 0. Oinical and physiologicsignificanceoflocaltissue renin-angiotensin 
systems. Am J Med. 1989;87(suppl 68) 19-23. 
3. Gampell DJ.Circulating andtissueangiotensinsystems.J Clin Invest. 1 987;79:1-6. 
4. Lever AF. Renin: endocrine, paracrine, or part-paracrine control of blood pressure. 
Am J Hypertension 1989;2:276-285. 
5. Cambell OJ. Extrarenal renin and blood pressure regulation: an alternative viewpoint. 
Am J Hypertension 1989;2:266-275. 
6. Sealy JE, Rubattu S. Prorenin and renin as separate mediators of tissue and circulating 
systems.Am J Hypertension. 1 989;2:356-366. 
7. Chanser D, DussauleJC,Ardaillou N, Ardaillou R. Identification and regulation of renin in human 
cultered mesangial cells. Am J. Physiol. 1 987;21 :F32-F38. 
8. Dzau VJ, Kreisberg J. Cuttered glomerular mesangial cells contain renin: influence of calcium 
and isoproterenoL J Gardiovasc PharmacaL 1 986;8:(suppl 1 O):S6-S1 0. 
9. Naruse K, Murakoshi M, Osamura RY eta!Jmmunohistochemicar evidence for renin in human 
endocrine tissues. J Clin Endocrinor Metab. 1985;61 :172-177. 
10. DeschepperCF, Mellon SH, Cumin F. Baxter JD, Ganong WF. Analysis by immunohistochemistry 
and in situ hybridisation of renin and its mRNA in kidney, testis, adrenal and piturtary of the rat. 
Proc Natl Acad Sci USA. 1986;83:7552-7556. 
11. Ganten D, Printz M, Philips Ml, Scholkens BA. The renin-angiotensin system in the brain. 
Exp Brain Res 1982;48:3-15. 
12. Glorioso N, Atlas SA. laragh JH, Jewelewicz R, Sealy JE. Prorenin in high concentrations in 
human follicularfluid. Science 1986;223:1422-1424. 
25 
13. Derkx FHM. Alberda AT, DeJong FH, Zeilmaker GH, Schalekamp MADH. Source of plasma 
prorenin early and late in pregnancy. Observations in a patient with primary ovarian failure. 
J Clin Endocrinol Metab 1987;65:349. 
14. Re R, FallonJT, Ozau V, QuaySC, HaberE. Renin synthesis by canineaorticsmooth muscle 
cells in cutture. Ule Sci 1982;30:99-106. 
15. Lilly LS, Pratt RE, Alexander RW, Larson DM, Ellison KE, Gimbrone MA, Dzau VJ. Renin expres-
sion by vascular endothelial cells in cutture. Circ Res 1985;57:312-318. 
16. Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension 1986;8: 
553-559. 
17. Swa!esJD, AbramoviciA, BeckF, Thurston H.Arterialwall renin. 
J Hypertension 1983;1(suppl) 17-22. 
18. Shaw KJ, Do YS, Kjos S, Anderson PW, Shingawa T, Dubeau L, Hsueh WA. Human decidua 
is a major source of renin. J Clin Invest 1989;83:2085-2092. 
19. Do YS, Sherrod A, Lobo RA, Paulsen RJ, Shinagawa T, Chen S, Kjos S, Hsueh WA. Human 
ovarian theca cells are a source of renin. Proc Natl Acad Sci USA 1988;85:1975-1961. 
20. Sealy JE, Goldstein M, P~arresi T, Kudlak TT, Glorioso N, Fiamengo SA, Laragh. Prorenin 
secretion from human testis: no evidence for secretion of active renin or angiotensogen. 
J Clin Endocrinol Metab 1988;66:974-978. 
21. Lumbers EA. Activation of renin in amniotic fluid by low ph. Enzymologia 1971 ;40:329-336. 
22:. Do YS, Shinagawa T, Tam H, lnagamiT, Hsueh WA. Characterisation of pure human renal renin: 
evidence for a subunit structure. J Bioi Chern 1987;262:1 037-1043. 
23. Galen FX, DevauxC, GuyenneT, MenardJ, Corvol P. Multipleformsofhuman renin: purification 
and characterization. J Bioi Chern 1979;254:4848-4855. 
24. Yokosawa H. Holladay LA, Jnagami T, Haas E, Murakami K. Human renal renin: complete 
purification and characterisation. J Bioi Chem 1980;255:3498-3502. 
25. Miyazaki H, FukamizuA, HiroseS, HayashiT, Hori H, Ohkubo H, NakanishiS, Murakami K. 
Structureofthe human renin gene. 
Proc Natl Acad Sci 1984;81:5999-6003. 
26. HardmanJA, Hort YJ, CatanzaroDF, TellamJT, BaxterJD, Morris BJ, ShineJ. Primary structure 
ofthehuman renin gene. DNA.1984;3:457-488. 
27. Hobart PM, FoglianoM, O'Connor SA, Schafer 1M, ChirgwinJM. Human reningene:structureand 
sequence analyses. ProcNatiAcadSci.1984;81 :5028-5030. 
26. Fritz LC,ArfstenAE, Dzau Vj,AtlasSA, Baxter JD, FiddesJC, ShineJ, CoferCL, KushnerP, Ponte 
PA. Characterization of human prorenin expressed in mamalian cells from cloned eDNA. Proc Natl 
Acad Sci1986;83:4114-4118. 
29. PrattRE, CarletonJE, RichieJP, HeusserC,Dzau VJ. Human renin biosynthesis and secretion 
in normal and ischaemic kidneys. Proc Natl Acad Sci 1987;84:7837-7840. 
30. Hirose S, Kim SJ, Miyazaki H, Park YS, Murakami K. Jn vitro biosynthesis of human renin and 
identification of plasma inactive renin as an activation intermediate.J Bioi Chern. 1985;260:16400-
18406. 
26 
31. Sessler FM, Jacquez JA, Malvin RL Different production and decay rates of six renin forms 
isolated from rat plasma. Am J Physiol1988;250:251-557. 
32. Kim S, Hiruma M, lkemoto F, Yamamoto K. Importance of glycosylationfor hepatic clearance 
of renal renin. Am J Physiol1988;255:642-651. 
33. Faust PL, ChrigwinJM, Kornfeld S. Renin, a secretory glycoprotein,acquires phoshomannosyl 
residues. J Cell Bioi. 1 987;1 05:1947-1955. 
34. Fritz LC, Haidar MA, Arfsten AE, Schilling JW, Carilli C, Shine J, Baxter JD, Reudelhuber TL. 
Human renin is correctly processed and targeted to the regulated secretory pathway in mouse 
pituitary AtT-20 cells. J Bioi Chem. 1987;282:12409-12412. 
35. Pratt RE, Flynn JA, Hobart PM. Paul M, Dzau VJ. Different secretory pathways of renin from 
mouse cells translected with the human renin gene. J Bioi Chern. 1987;283:3137-3141 
38. Shinagawa T, Do YS, Baxter JD, Carilli C, Schilling J, Hsueh WA. Identification at an enzyme 
in human kidney that correctly processes prorenin. Proc Natl Acad Sci. 1990;87:1927-1931. 
37. Kelly RB. Pathways of protein secretion in eukaryocytes. Science 1988;230:25-32. 
38. Anderson PW, Macaulay l, Do YS, Sherrod A, d'Ablaing G, KossM, ShinagawaT, Tran B, Montz 
FJ, Hsueh WA. Extrarenal-secreting tumors: insights into hypertension and ovarian renin 
production. Medicine 1990; 68:257-268. 
39. HsuehWA, Baxter JD. Human prorenin. Hypertension 1991 ;17:469-479. 
40. SealyJ E, Atlas SA, Laragh. Prorenin and other large molecu!arweghtformsof renin. En doer Rev 
1980;1 :385-391. 
41. Hsueh WA, Carlson EJ, Luetscher JA, GrislisG. Big renin in plasmaofhealthysubjectson high 
sodium intake. lancet 1978;1 :1281-1264. 
42. Derkx FHM, Tan-Tjong Hl, Wenting GJ, Boomsma F, Man in t Veld AJ, Schalekamp MADH. 
Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery 
stenosis. Hypertension 1983;5:244. 
43. DerkxF, Wenting G, Man in Weld AJ, Verhoeven R, Schalekamp MADH. Control of enzymatically 
inactive renin in man undervarious pathological conditions: implications for the measurements in 
peripheral and renal plasma. Clin Sci Mol Med 1978;54:529-538. 
44. Derkx FHM. Human prorenin. Thesis 1987. 
45. Derkx FHM, Schalekamp MADH. Human prorenin: pathophysiology and clinical implications. 
Clin Exp Hypertension Theory Pract 1988;A 1 0:1213-1225. 
46. Sealey JE, Moon C, Laragh JH, Atlas SA. Plasma prorenin in normal, hypertensive and a nephric 
subjects and its effect on renin measurements. Circ Res.1977;40: 141-45. 
47. Derkx FHM, Tan-Tjiong H, Wenting G, Boomsma F. Man intVeldAJ, Schalekamp MADH. 
Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in 
women taking oral anticonceptives. J Clin Endocrinol Metab. 1986;63:1 008-1015. 
48. SealyJE, McCord D, Taufeld PA,Aies KA, Druzin ML,AtlasSA, laragh. Plasmaprorenininfirst-
trimester of pregnancy: relationsship to changes in chorionic gonadotropin. Am J Obstet 
Gynecol.1985;153:514-519. 
27 
49. Sealy JE, Atlas SA, Glorioso N, Manapat H, LaraghJH. Cyclic secretion of prorenin during the 
menstrual cycle: synchronisation with luteinizing hormone and progesterone. Proc Nat! Acad 
Sci.1985;82:8705-8709. 
50. ltskovitz J, Sealy JE, Glorioso N. Plasma prorenin response to chorionic gonadotrhophin in 
ovarian-stimulated women: correlation with the number of ovarian follicles and steroid hormone 
concentrations. Proc Natl Acad Sci. 1987;84:7285-7289. 
51. Derkx FHM. Alberda AT. Zeilmaker GH. Schalekamp MADH. High concentrations of immu-
noreactive renin, prorenin and enzymatically active renin in human follicular fluid. Br J Obstet 
Gynecol1987;94:4-9. 
52. Glorioso N. Atlas SA. LaraghJH. Jewelewicz R. SealyJE. Prorenin in high concentrations in human 
follicularfluid. Science 1988;233:1422-1424. 
53. DerkxFHM.AiberdaAT.DeJongFH,ZeilmakerGH,MakovitzJW,SchalekampMADH.Source 
of plasma prorenin early and late in pregnancy. Observations in a patient with primary ovarian 
failure. J Clin Endocrinol Metab 1987;65:349-354. 
54. Corvo! P. Tumor-dependent hypertension. Hypertension 1984;6:593-596. 
55. Corvo! P. Pi net F, Galen FX, Plouin PF, Chatellier G. Pagny JY, Corvo! MT, Menard J. Seven 
lessions from seven renin secreting tumors. Kidney lnt 1988;34(suppl25}:S38-S44. 
56. Leckie B, Mcintyre GD, Millan WD, Lindop GBM, Carachi R. Renin and inactive renin (prorenin} 
in the plasma of patients wtth malignant renal tumours. Clin Exp Hypertension 1987 A9:141-145. 
57. Fernandez LA, Olsen TG, Barwick twv. Renin in angiolymphoid hyperplasia with eosinophilia. 
Its possible effect on vascular proliferation. Arch Pathol Lab Med 1988;11 0:1131-1135. 
58. Ariza A, Fernandez LJ\., lnagamiT, KimJH, Manue!idisEE. Renin in glioblastoma muttiiormeand 
rts role in neovascularization. Am J Clin Pathol 1988;90:437 -441. 
59. NormanJT. The role of angiotensin Jl in renal growth. Renal Physiol Biochem 1991 ;14:175-185. 
80. NormanJ, Badie-Dezfooly B, Nord EP, Schlosser J, ChaudhariA, Fine LG. EGF-induced 
mitogenesis in proximal tubular cells: potentiation by angiotensin II. Am J Physior. 1987;253: 
F299-F309. 
61. Khairallah PA, RobertsonAL, Davila D. Effectsofangiotensin II on DNA, RNA and protein synthesis. 
In: Hypertension 1972, Genest J, Koiw E, Berlin, Springer-Vertag. 
62. Geisterter AA T, Peach MJ, Owens GK. Angiotensin induces hyperthrophy, not hyperplasy, of 
cultered rat aortic smooth muscle cells. Circ Res 1988:62:749-758. 
63. Taubment MB, Berk BC, lzumo S, Tsuda T, Alexander RW, Nadai-Ginard B. Angiotensin II in-
duces c-fos mRNA in aortic smooth muscle. J Bioi Chern 1989;284:526-530. 
64. Fernandez LA, Caride VJ, Twickler J, Galardy RE. Renin-angiotensin and development of col-
lateral circulation after renal ischemia. Am J Physioi1982;243:H889-H875. 
85. Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II.J Lab Clin Med 
1985;105:141-145. 
66. Owens GK.Influence of blood pressure on development of aortic medial smooth muscle hyper-
trophy in spontaneously hypertensive rats. Hypertension 1987;9:176-187. 
01. Wang D, Prewitt RL. Captopril reduces aortic and microvascular growth in hypertensive and 
normotensive rats. Hypertension 1990;15:68-77. 
28 
68. Admiraal PJJ. Derkx FHM, Danser AJ, Pieterman H, Schalekamp MADH. Metabolism and 
production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension 
1990;15:44--55. 
69. Danser AHJ, Koning MMG,Admiraal PJJ, Sassen LMA, Derkx FHM, Verdouw PD, Schalekamp 
MADH. Production of angiotensins I and II at tissue sites in the intact pig. Am J Physic! 
1992;263:H42S-H437. 
70. Schaectelin G, Regoli 0, Gross F. Qualitative assay and disappearance rate of circulating renin. 
AmJ Physiolt%4;200:1361-1364. 
71. Thurston H, SwalesJD, Hurst BC, Marks ES. Vascularrenin activ~y and blood pressure main-
tainanca in the rat. Hypertension 1979; 1 :643-649. 
72. Swales JD. Arterial wall or plasma renin in hypertension. Clinical Science 1979;56:293-298. 
73. Loudon M, Bing RF, Thurston H, SwalesJD. Arterial wall uptake of renal renin and blood pressure 
control. Hypertension 1983;5:629-634. 
74. Swales JD, Samani NJ. Vascular renin and hypertension. Uptake versus synthesis. 
Am J Hypertens 1990;3:890-892. 
75. Lenz T, Sealey JE, Lappe RW, Carilli C. Oshiro GT, Baxter JD, Laragh JH. Infusion of recom-
binant human pro renin into rhesus monkeys: effects on hemodynamics, renin-angiotensin-aldo-
sterone axis and plasma testosterone. Am J Hypertens 1990;3:257-261. 
76. Lenz T, Sealy JE, MaackT, James GO, Heinrikaon RL, Marion D, Laragh JH. HaH-Iife, hemody-
namic, renal, and hormonal effects of prorenin in cynomolgus monkeys. 
AmJ Physioi1991;29:R804-R810. 
77. Sealey JE, WMe RP, Laragh JH, Rubin AL. Plasma prorenin and renin in anephric patients. 
Circ Res 1977;41:17-21. 
78. SealeyJE,AtlasSA, LaraghJA. Proreninandotherlargemolecularweightfomns olrenin. Endocrinol 
Rev 1980;1:365-391. 
79. OerkxFHM, SchalekampMPA, Schalekamp MADH. Twostepprorenin-renin conversion.J Bioi 
Chern 1987;262:2472-2477. 
80. Atlas SA, Hesson TE, Sealey JE, LaraghJA Reversible acid-activation ofinactive renins: evidence 
favoring a unimolecular reaction. Clin Sci 1982;83:167s-170s. 
81. Sealy JE Rubattu S. Proreninand renin as separate mediators oftissueand circulating systems. 
AmJ Hypertension 1969;2:358-366. 
82. SealeyJE, LutterottiN, Rubattu S, CampbeiiWG, Gahnem F, HalamiJM, LaraghJH.Thegreater 
renin system. Hsprorenin-directedvasodilatorlimb. Relevancetodiabetes mei!Ous, pregnancy, and 
hypertension. Am J Hypertens 1991 ;4:972-977. 
83. Laragh JH. The renin system and four lines of hypertension research. 
Hypertension 1992;20:267-279. 
84. Halimi JM, Sealey JE. Prorenin in diabetes mell~us. Trends Endocrinol Metab 1992;3:270-275. 
85. AssaiJP, ChristliebAR. Plasma renin activity in diabetic acidosis. Clin Res.1972;20:382(abstract). 
86. Christlieb AR. Diabetes and hypertensive vascular disease. Am J Card. 1973;32:592-600. 
29 
87. Scott RS, Espiner EA, Donald RA, Livesey JA. Hormonal responses during treatment of acute 
diabetic ketoacidosis with constant insulin infusions. Clin Endocrinol. 1978;9:463-473. 
88. Waldhausl W, Kleinberger G, Kom A, Dudczak R, Bratusch-Marrain P, Nowontny P. Severe 
hyperglycaemia: effects of rehydration on endocrine derangements and blood glucose concen-
tration. Diabetes 1979;28:577-584. 
89. OuigleyC,SullivanPA,GonggrijpH,CrowleyMJ,FenissJB,O'SullivanOJ.Hyperaldosteronism 
in ketoacidosis and in poorty controlled non-ketoticdiabetes.lrJ Med Sci 1982;151 :135-139. 
90. Sulflvan PA, GongrijpH, CrowleyMJ, FerissJB, O'SullivanDJ. Plasma angiotensin II concentrations 
in diabetic acidosis and in hyperosmolar non~ketotic hyperglycaemia. 
Acta Diabetol Lat 1981 ;18:1 $-146. 
91. ChristliebAR,AssaiJP, KatsilambrosN, WilliamsGH, KozakGP,SuzukiT. Plasma renin activity 
and blood volume in uncontrolled diabetes. Diaibetes.1975;24:190-193. 
92. Christlieb AR. Renin-angiotensin-aldosterone system in diabetes mellitus. 
Diabetes.1976;25:820-825. 
93. De Chatel R, Weidmann P, FlammerJ,ZieglerWH, Beretta-PiccoliC, VetterW, Reubi FC. So-
dium, renin, aldosteron, catecholamines, and blood peressure in diabetes mellitus. Kidney Int. 
1977;12:412-421. 
94. Burden AC, Thurston H. Plasma renin activity in diabetes mellitus. Clin Science.1979;56:255-
259. 
95. FerrissJB, O'HareJA, KelleherCCM, Sullivan PA, Cole MM, Ross HF, O'Sullivan OJ. Diabetic 
control and the renin-angiotensin system, catecholamines, and blood pressure. 
Hypertension 1985;7(supplll):ll53-1163. 
96. O'HareJA, FerissJB, TwomeyBM, GongrijpH, O'Sullivan OJ. Changes in blood pressure, body 
fluids, circulating angiotensin II and aldosterone, with improved diabetic control. 
ClinSci 1982;63:415-418. 
97. Christensen NJ. Plasma norepinephrine an epinephrine in untreated diabetics, during fasting and 
after insulin administration. Diabetes 197 4;23:1-8. 
98. Sullivan PA, GonggrijpH, Crowley MJ, FerissJB, O'Sullivan OJ. Plasma angiotensin II and the 
control of diabetes mellitus. Clin Endocrinol1980;13:387-392. 
99. Christiansen JS, GieseJ. Damkjar M, Parving HH. The renin-angiotensin system and kidney 
function during inrrial insulin treatment in diabetic man.ScanJ Clin Lab I nvest1988;48:451-456. 
100. Gossain VV, Werk EE, Sholiton W, Srivastava L. Knowles HC. Plasma renin activity in juvenile 
diabetes mellitus and effectofdiazoxide. Diaibetes.1975;24:833-835. 
101. Hauger-Kievene JH, De G. Moyano MBB. The renin-angiotensin system in diabetes melrrtus. 
Acta Physiologica Latina America. 197 4;24:41 0-424. 
102. Drury PL. BodanskyHJ, OddieCJ, CudworthAG, EdwardsCRW.Increased plasma renin activity 
in type I diabetes with microvasculardisease.Ciin Endocrinol.1982;16:453-461. 
103. Drury PI, Bodansky HJ, OddieCJ, Edwards CRW. Factorsinthecontrolofplasma renin activity 
and concentration in type I Qnsulin-dependent) diabetes. Clin Endocrinol1984;20:607-618. 
104. Drury PL, Bodansky HJ. The relationship of the renin-angiotensin system in type I diabetes to 
microvascular disease. Hypertension.1985; 7 (supplll) 84-89. 
30 
105. Christlieb AR. Munichoodappa C, Braaten JT. Decreased response of plasma renin activity to 
orthostasis in diabetic patients with orthostatic hypotension. Diabetes. 1974;23:835-840. 
106. Perez GO, Lespier L, JacobiJ, Oster J R, Katz FH, VaamondeCA, Fishman LM. Hyporeninemia 
and hypoaldosteronism in diabetes mellitus. Arch Intern Med. 1977;137:852-855. 
107. TuckML, SambhiMP, Levin L,Hyporenimic hypoaldosteronism in diabetes mellitus. Studies of 
the autonomic nervous system' s control of renin release. Diabetes.1979;237 -241. 
108. Femandez-Cruz A. Noth R, Lassman MN, Hollis JB, Mulrow PJ. Low plasma renin activity in 
normotensive patients with diabetes mellitus: relationship tO neuropathy. 
Hypertension 1981;3:87-92. 
109. Trujillo A, Eggena P. BarrettJ, Tuck M. Renin regulation in type II diabetes mellitus: influence 
of dietary sodium. Hypertension. 1989;13:200-205. 
110. ChristliebAR,JankaH-U, Kraus B. Gleason RE, lcasas-GabraiEA,Aiello LM, Cabral BV, Solano 
A. Vascular reactivity to angiotensin II and to norepinephrine in diabetic subjects. 
Diabetes.1976;25:268-27 4. 
111. Moss S, Oster JR, Perez GO, Katz FH, Vaamande. Renin-aldosterone responsiveness in 
uncomplicated juvenile-type diabetes mellitus. Horm Res 1978;9:130-136. 
112. Sunderlin FS, Anderson GH, Street en DHP, Blumenthal SA. The renin-angiotensin-aldosterone 
system in diabetic patients with hyperkaliaemia. Diabetes.1981 ;30:335-340. 
113. Feldt-Rasmussen B. Mathiesen ER, Deckert T, GieseJ, Christensen NJ, Bent-Hansen L, Niel-
sen MD. Central role for sodium in the pathogenesis of blood pressure changes independent 
of angiotensin, aldosterone and catecholamines in type I (insulin-dependent) diabetes mellitus. 
Diabetologia. 1987;30:61 Q-617. 
114. Weidmann P. Beretta-Piccoli C. Trost BN. Pressor factors and responsivness in hypertension 
accompanying diabetes mellitus. Hypertension 1987:7(suppl):33-42. 
115. O'Hare JA, FerrisJB, Brady D, Twomey B, O'Sullivan OJ. Exchangeable sodium and renin in 
hypertensive diabetic patients with and wtthout nephropathy. Hypertension.1985:7(supplll): 
43-48. 
116. Weidmann P, Ferrari P. Central role of sodium in hypertension in diabetic subjects. 
Diabetes Care 1991 ;14:220.232. 
117. Roland JM, O"HareJA, Watters G, Corral! RJM. Sodium retention in response to slaine infusion 
in uncomplicated diabetes mellttus. Diabetes Res. 1986;3:213-215. 
118. Burg Mb. Renal handling of sodium, chloride, water, aminoacidsandglucoex.ln: BrennerBM, 
Rector FC, eds The Kidney. Saunders. 1981 :328-370. 
119. Claussen T. Regulation of active Na+K+transport in skeletal muscle.Physiological Revieuws 
1986;86:542-580. 
120. De Fronzo. The effect of insulin on renal sodium metabolism. Diabetologia.1981 ;21 :165-171. 
121. Christensen NJ. Plasma catecholamines in long-term diabetics with and without neuropathy and 
in hypophysectomized subjects. J Clin lnvest.1972;51 :779-787. 
122. Neubauer B. Christensen NJ, Aarhus MO. Norepinephrine, epinephrine, and dopamine contents 
of the cardiovascular system in long-term diabetes. Diabetes.1976;25:6-1 0. 
31 
123. Cryer PE. Silverberg AB, Santiago JV, Shah SO. Plasma catecholamines in diabetes. 
AmJ Med.1978;64:407-416. 
124. FerrissJB, Sullivan PA, Gongrijp H. ColeM, O'Sullivan OJ. Plasma angiotensin II and aldosterone 
in unselected diabetic patients. Clin Endocrinc>.1982; 17:261-269. 
125. Day RP, Luetscher JA, Gonzales CM. Occurence of big renin in human plasma, amiotic fluid 
and kidney extracts.J Clin Endocrine! Metab.1975;40:1078-1093. 
126. de Leiva A, Christlieb AR, Melby JC, Graham ChA, Day RP, Luetscher JA, Zager PG. Big renin 
and biosynthetic defect of aldosterone in diabetes mellitus. N Engl J Mecl. 1976;639-643. 
127. Corvo! P, MenardJ. From the renin gene to renin inhibitors.Adv Nephro! 1987;16:17-32. 
128. Bryer-Ash M, Fraze EB, Luetscher JA Plasma renin and prorenin ( inactive renin) in diabetes 
mell~us: effects of intravenous furosemide.J Clin Endocrine! Metab. 1988;66:454-458. 
129. Manchandia MR, Gossain W, Michelakis Rovner. Plasma cryoactivated renin and active renin 
in diabetes mellitus.J Clin Endocrine! Metab. 1981 ;53:1 025-1 029. 
130. Fuji S, Shimojo N, Wada M, Funae Y. Plasma active and inactive renin in patients with diabetes 
me!Gtus. Endocrine! Japon. 1980;27:65-88. 
131. Bryer-Ash M, Ammon RA, Luetscher JA. Increased inactive renin in diabetes mellitus without 
evidence of nephropathy. J Clin Endocrine! Metab 1983;557-561. 
132. LuetscherJA, Kraemer FB, Wilson DM,SchwartzHC, Bryer-Ash M.lncreased plasma inactive 
renin in diabetes mellitus: a marker of microvascular disease. N Engl J Meet 1985;3121 :1412-
1417. 
133. LuetscherJA, BiaJekJW, Grislis G. Human kidney cathepsin Band H activated and lower the 
molecular weight of human inactive renin. Clin Exp Hypertens.1982;4:2149-2158. 
134. Coradello H, Pollak A, Pagano M, LebanJ, Lubec G. Non-enzymaticglycosylation of cathepsin B: 
possible influence on conversion ofproinsulinto insuiin.IRCS Med Sci 1981 ;9:766-777. 
135. HsuehWA, Carlson EJ, DzauV .Characterizationofinactivereninfromhuman kidney and plas-
ma. Evidence for a renal source of circulating inactive renin. J Clin lnvest.1983;71 :506-517. 
136. Chimori K, Miyazaki S, KosakaJ, SanakaA, Yasuda K, Mirua K. Thesignificanceofautonimic 
neuropathy in the elevation of inactive renin in diabetes mellitus. 
Clin Exp Hypertension 1987;A9:1-18. 
137. Misbin Rl, Grant MB, PeckerMS ,Atlas SA. Elevated levels of plasma prorenin in diabetic and 
nondiabetic patients withautonomicdysfunction.J Clin Endocrine> Metab 1987;64:984-968. 
138. Leutscher JA, Kraemer FB. Microalbuminuriaand increased plasma prorenin. prevalence in 
diabeticsfollowedupforfouryears.Arch Intern Med. 1988;937-941. 
139. Luetscher JA, Kraemer FB, Wilson OM. Prorenin and vascular complications of diabetes. 
AJH 1989;2:362-388. 
140. Amemiya S, Ishihara T, Higashida K, Kusano S. Ohyama K, Kate K. Attered synthesis of renin 
in patients with insulin-dependent diabetes: plasma prorenin as a markerpredictingthe evolution 
of nephropathy. Diabetes Research and Clinical Practice 1990;1 0:115-122. 
141. Wilson DM, Luetscher JA. Plasma prorenin-activity and complications in children with insulin-
dependent diabetes melfrtus. N Eng! J Med 1990;323:11 01-11 06. 
32 
Chapter2 
HIGH PlASMA PRORENIN IN DIABETES MElLITUS AND ITS CORRELATION 
WITH SOME COMPliCATIONS 
SUMMARY 
Plasma prorenin is abnormally high, whereas renin is normal or even low, in many 
patients with longstanding diabetes mellitus complicated by microvascular disease. 
Nephropathy or autonomic neuropathy have been put forward as a cause. We found that 
in 223 consecutive diabetics prorenin correlated positively with serum creatinine, the 
presence of macroalbuminuria(>250 mg/L) and the presence of diabetic retinopathy, 
particularly the proliferative type. This correlation did not depend on the presence of 
neuropathy or on whether the patient was on insulin or not. It was also independent of 
sex, age, duration of diabetes, blood pressure and the blood levels of glucose and 
HbA 1 c. The association between elevated prorenin and retinopathy remained significant 
after adjustmentfor creatinine and the presence of macroalbuminuria. Of the whole group 
of diabetics 94 consecutive patients were assessed for the presence of microalbunimuria 
(30-300 mg/24h). Independently of the presence of micro- or macroalbuminuria, the 
mean level of prorenin was not above normal in the patients without retinopathy and was 
2-3times normal in those with proliferative retinopathy. Thus, retinopathy appears to be 
a more important determinant of abnormally high prorenin than nephropathy. In addition, 
the renal vein-to-artery ratio of prorenin in 7 diabetics with both advanced nephropathy 
and proliferative retinopathy was not elevated, despite the high peripheral vein prorenin 
level and the impaired renal perfusion. Thus the abnormally high prorenin in these 
patients could not be explained by abnormal secretion by the kidneys. Finally, prorenin 
was not high in 16 non-diabetics with loss of sympathetic activity due to chronic 
autonomic neuropathy, which indicates that, in the absence of diabetes, this type of 
autonomic failure is not sufficientto cause the high prorenin levels seen in diabetics. Our 
findings are evidence that abnormally high plasma prorenin in diabetes is not an 
immediate consequence of altered glucose metabolism. This abnormality is related to 
the development of microvascular disease in the eye and the kidney, and is, at least 
in part, due to either decreased clearance of prorenin from the circulation or increased 
production from extrarenal sources or both. 
INTRODUCTION 
Prorenin is an inactive precursor of renin, which in plasma is the rate limiting enzyme 
responsible for the formation of angiotensin II, a peptide with important vascular actions. 
In longstanding diabetes mellitus complicated by microvascular disease the plasma 
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level of prorenin is often 2-3 times normal (1.2), whereas renin is within or below the 
nonmal range (3,4). The cause of the elevated plasma prorenin in diabetes is unknown. 
Prorenin is synthesized in the renal juxtaglomerular cells, where it is converted to renin. 
The kidney releases both renin and prorenin into the circulation (5,6), and it is possible 
that in diabetic nephropathy the quantity of prorenin released by the kidneys is 
disproportionally high because of abnormal enzyme processing or secretion (7). 
Diabetic autonomic neuropathy has also been put forward as a cause. Loss of normal 
adrenergic stimulation of the renal juxtaglomerular cells might lead to a decrease in the 
secretion of renin stored in these cells and to a compensatory increase in the synthesis 
and secretion of prorenin. High plasma levels of prorenin have indeed been documented 
in some diabetics with autonomic neuropathy (8,9). However, autonomic neuropathy 
was not the only diabetic complication in these patients. 
In the present study we examined in a group of diabetics the statistical correlations 
between the plasma level of prorenin and the presence of nephropathy, neuropathy and 
retinopathy. We also studied a group of non-diabetic patients with loss of sympathetic 
function due to autonomic neuropathy in order to examine whether loss of adrenergic 
stimulation, in the absence of diabetes and its complications, is associated with an 
elevated plasma prorenin. We finally measured plasma prorenin in the renal veins of 
patients with diabetic nephropathy in an attempt to demonstrate increased secretion of 
prorenin by the kidney. 
SUBJECTS AND METHODS 
Outpatients with diabetes mellitus. 
This group (n=223) consisted of all diabetics attending our outpatient facilities in three 
consecutive months, with the exception of patients with overt cardiac failure, hepatic 
disease or renal failure (serum creatinine above 200 jJmoi/L). Patients on drugs likely 
to affect the plasma level of renin were also not included. Some clinical characteristics 
of these patients are given in Table 1. In the study group 136 were on insulin, 82 on oral 
antidiabetic drugs and 5 on diet alone. The patients were seen by an internist and an 
ophthalmologist, who were unaware ofthe results olthe renin measurements. Non-timed 
overnight urine collections obtained at two different days were tested lor the presence 
of protein. Macroalbuminuria was defined as albumin above 250 mg/L in each of the 
two samples. An assessment of microalbuminuria was made in the patients visiting the 
outpatient clinic in the last two months excluding those with macroalbuminuria and 
those with a history of kidney or urinary tract disease. Clinical characteristics of these 
patients are given in Table 2. Microalbuminuria was defined as albumin between 30-300 
mg/24h in at least two out of three consecutive 24 hour urine collections (1 0). 
Diabetic retinopathy was assessed by direct and indirect ophthalmoscopy after 
pupillary dilatation and in most cases also by fluorescein angiography. Grading of the 
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severity of diabetic retinopathy was based on the findings at ophthalmoscopy and was 
done by the ophthalmologist. 
Table 1. Clinical characteristics of diabetic patients with and without macroalbuminuria 
Macroalbuminuria 
p value 
absent present 
Sex female/male n 89f72 26/36 ns 
Age median yr 56 54 ns 
range 21-87 20-92 
Duration median yr 9 15 p< 0.05 
of diabetes range 1-55 1-47 
Insulin on insulin/not on insulin n 95/66 41/21 ns 
treatment 
Neuropathy absent/present n 127/34 44/18 ns 
Diabetic absent/present n 84(77 15/47 p < 0.001 
retinopathy background/proliferative n 49/28 11/36 p < 0.001 
HbA1c mean (sd) % 9.8 (1.2) 10.1 (0.9) ns 
Serum creatinine mean (sd) j.!moi/L 82 (18) 101 (20) p < 0.001 
above 11 0 llmoi!L n 10 19 p < 0.001 
Blood pressure 
systolic mean (sd) mmHg 149 (24) 148(21) ns 
diastolic mean (sd) mmHg 81 (12) 86(12) ns 
Renin geometric mean mU/L 12.5 15.7 ns 
95% conf.interval 2.4-65.0 3.3-76.4 
Prorenin geometric mean mU/L 196 373 p < 0.001 
95% conf.interval 44.1-873 88.0-1579 
ns; not significant (p > 0.05). 
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Table 2. Clinical characteristics of diabetic patients with and without microalbuminuria 
Microalbuminuria 
p value 
absent present 
Sex female/male n 36/38 10/10 ns 
Age median yr 49 55 p < 0.05 
range 21-76 38-86 
Duration median yr 11 13 ns 
of diabetes range 1-39 1-45 
Insulin on insulin/not on insulin n 43/31 12/8 ns 
treatment 
Neuropathy absenVpresent n 6217 17/3 ns 
Diabetic absenVpresent n 39/35 6/14 ns 
retinopathy background/proliferative n 17/18 9/5 ns 
HbA1c mean (sd) % 9.7(1.2) 10.3 (0.9) ns 
Serum creatinine mean (sd ) [lmoi/L 79 (19) 80 (20) ns 
above 11 0 [lmoi/L n 4 2 ns 
Blood pressure 
systolic mean (sd) mmHg 144 (24) 160 (21) p < 0.05 
diastolic mean (sd) mmHg 79 (19) 86 (12) ns 
Renin geometric mean mU/L 11.4 7.6 ns 
95% cont. interval 2.1-61.8 1.6-35.1 
Prorenin geometric mean mU/L 166 163 ns 
95% conf. interval 43.0-632 40.1-653 
ns:::: not significant (p > 0.05). 
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For the purpose of the present analysis, diabetic retinopathy was categorized as either 
background retinopathy or proliferative retinopathy. Background retinopathy was cha-
racterized as the presence of microaneurysms, whether or not combined with hemorr-
hages and hard exudates (11 }. Eyes with preproliferative retinopathy, characterized by 
multiple cotton wool spots, venous abnormalities, beading and duplications, intraretinal 
microvascular abnormalities and diffuse large blot hemorrhages, were also categorized 
as background diabetic retinopathy. Patients with new vessels anywhere in the retina 
in either eye were categorized as having proliferative retinopathy. Ofthe 65 patients with 
proliferative diabetic retinopathy 55 had been treated by laser photocoagulation of one 
or both eyes. 
Sensory or motor fibre neuropathy was defined as diminished sense of vibration at 
the lower or upper extremities and loss of Achilles or patellar tendon reflexes (12}, which 
generally is associated with other signs of neuropathy or with symptoms, such as 
sensory loss, distal paresthesia or pain. No attempt was made to exclude or diagnose 
autonomic neuropathy but none ofthe patients had symptomatic orthostatic hypotension. 
Table 3. Plasma levels of prorenin in various categories of diabetics 
Factor Category n Pro renin Significance 
mU/L 
Sex Female 117 194(43.0-844} p < 0.001 
Male 106 291 (63.6-1330} 
Insulin On insulin 87 203 (49.5-827} p < 0.01 
Not on insulin 136 262(51.5-1330} 
Proteinuria Absent 161 193 (43.2-848} p<0.0001 
(>300 mg/L} Present 62 368 (85.7-1580} 
Neuropathy Absent 172 219 (46.0-1 040} ns 
Present 51 276 (54.6-1400} 
Retinopathy Absent 99 165 (46.5-589} 
Background 60 228 (51.6-1010} p < 0.01 
Proliferative 64 416 (101-1710} p < 0.001 
Prorenin is given as geometric mean and 95% confidence interval. ns ~not significant 
(p > 0.05}. The difference between patients with and without neuropathy was of borderline 
significance (p ~ 0.06}. 
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Patients with diabetic nephropathy. 
Serum creatinine in these patients (n=7) was above 300 11moi/L and total effective renal 
plasma flow measured by 1311-Hippuran clearance (13) was less than 130 mUmin. 
They also had proliferative diabetic retinopathy. There were no symptoms or signs of 
autonomic neuropathy. Orthostatic hypotension was absent and the Valsalva response 
was normal. Peripheral venous plasma prorenin was elevated (above 360 mU/L) in each 
patient. The patients were studied at the time they were undergoing aortic angiography 
in preparation of receiving a kidney transplant. Blood was sampled from the aorta and 
renal veins before the contrast injection was given. 
Non-diabetic patients with chronic autonomic neuropathy. 
These patients (n=16, age 34-80 yr) have been described in detail (14) and some 
relevant clinical data are given in Table 3. All had severe incapacitating orthostatic 
hypotension. Disruption of the integrity of the baroreflex arc with loss of normal 
sympathetic function was confirmed by the absence of a systolic blood pressure 
overshoot in phase4 ofthe Valsalva response. The resting plasma level of norepinephrine 
was low in the patients with pre- or postganglionic lesions. In all patients plasma 
norepinephrine did not respond to head up tilt on a tilting table for30 min causing a blood 
pressure drop of 20-25 mmHg systolic and 10-15 mm Hg diastolic. 
Blood sampling. 
In the group of outpatients with diabetes blood samples for measuring renin and prorenin 
were drawn from an antecubital vein afterthe patients had rested for30 min in the sitting 
position. Blood samples for measuring creatine, glucose and glycosylated hemoglobin 
(HbA1c, normal range 5.5-7.3 %) were also taken. In the non-diabetics with autonomic 
neuropathy peripheral venous blood was collected in the lying position. During the renal 
vein catheterisation studies blood was sampled from the renal vein on each side and 
at the same time from the abdominal aorta. 
Measurements of renin, pro renin and norepinephrine. 
The plasma levels of renin and prorenin were measured with the enzyme kinetic assay, 
in which the angiotensin I generated by plasma in vitro was quantitated by 
radioimmunoassay (15). For measuring prorenin, the proenzyme was quantitatively 
converted to renin at 4 oc by immobilized trypsin (5, 16). That we were measuring 1rue' 
prorenin, and not a renin-like enzyme, was supported by comparing the results of the 
enzyme kinetic assay with those of a direct radioimmunoassay (16,17). The latter was 
a solid phase sandwich assay in which two monoclonal human renin antibodies, which 
reacted equally well with kidney renin and chorionic cell culture prorenin, were used. 
Measurements in plasma samples from diabetics with prorenin levels ranging from 100-
1000 mU/L, as determined by the indirect enzyme kinetic assay, showed excellent 
agreement between the direct and indirect assays. The specific enzymatic activity of 
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in vitro activated prorenin in plasma of diabetics was 0.8 (0.1) mUing (mean,sd, n=8), 
which is not different from the specific activity of purified human kidney renin (17). 
Normal levels of renin and prorenin in males (n=50, age 21·54 yr) were 18.2 ( 7.5-
52) and 166 mUll (65-300) mUll respectivily (geometric mean, range). In normal 
women in the first 2-12 days of the menstrual cycle (n=54, age 20-37yr) renin was 15.4 
(4.7-59) mUll and prorenin was 151(62-357) mUll (16). 
Plasma norepinephrine was measured by high performance liquid chromatography 
(14). In normal subjects (n=57, age 28-78 yr) plasma norepinephrine was 1.5 (0.6-3.6 
nmoi!L (geometric mean,range). 
Table 4. Correlations of (log) prorenin with various factors in diabetes 
r Significance 
Age 0.07 ns 
Duration of diabetes 0.24 p < 0.001 
Systolic blood pressure -0.07 ns 
Diastolic blood pressure 0.02 ns 
Serum creatinine 0.37 p < 0.001 
Blood glucose 0.11 ns 
HbA1c 0.09 ns 
r = Pearson correlation coefficient. ns =not significant (p > 0.05). 
Assessment of macro- and microalbuminuria. 
Macroalbuminuria was assessed in non-timed overnight urine samples with dipstick 
(Aibustix, Miles, Naperville, ILL, USA), which has a detection limit of 250 mgll. In case 
of a trace reaction, the urine sample was tested by the quantitative biuret reaction. 
Macroalbuminuria was defined as dip-stick positive or biuret reaction of protein above 
250 mgll in two out of two overnight urine samples. Microalbuminuria was assessed 
in three consecutive 24 hour urine collections with radial immunodiffusion in agarose 
gel (18). The gel contained 30 Ill undiluted antiserum against human serum albumin 
(Dakopatts, Glostrup, Denmark) per 10 ml gel. The lower limit of detection was 2 mgl 
Land the interassay variability was 8 %. Microalbuminuria was defined as albuminuria 
of 30-300 mg/24h in at least two of the 24 hour urine collections, while all three 24 hour 
urine collections were dipstick-negative. 
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Table 5. Effects of diabetic retinopathy on mean (log) prorenin and standard errors (SE) estimated by 
muttiple regression analysis 
Diabetic retinopathy grouping not Diabetic retinopathy grouping 
included included 
Factor 
Effect SE Pvalue Effect SE PValue 
Constant (intercept) 0.94 026 1.09 024 
Creatinine 0.024 0.005 <0.0001 0.023 0.05 <0.001 
Creatinine square -0.000097 0.000024 <0.0001 -0.000092 0.000022 0.0001 
Insulin therapy 0.08 0.04 0.06 0.02 0.04 0.7 
Proteinuria (>250 mg/L) 0.19 0.05 <0.001 0.10 0.05 <0.05 
No retinopathy Not tested -0.10 0.05 <0.05 
Proliferative diabetic retinopathy Nottested 0.19 0.08 0.001 
Effects denote mean increase of (log) pro renin by: 1 U creatinine or creatinine square, insulin therapy vs. 
noinsulintherapy (1 vs.O), proteinuria presentvs. absent (1 vs.O), no diabetic retinopathy vs. background 
diabetic retinopathy (1 vs.O), and proliferative diabetic retinopathy vs. background diabetic retinopathy 
(1 vs.O). 
Table 6. Plasma levels of prorenin, renin and norepinephrine in non-diabetics with chronic autonomic 
neuropathy 
Patient Site of lesion Etiology Prorenin Renin Norepinephrine 
no. mUlL mUlL nmci!L 
Hl Preganglionic Parkinson's disease 141 5.1 0.62 
59-380 1.9-15.3 0.19-2.6 
7-11 Postganglionic Amyloidosis 189 10.2 0.33 
121-327 5.0-30.4 0.09-1.2 
12 Postganglionic Progressive AF 103 8.1 026 
13 Postganglionic Progressive AF 271 0.8 0.75 
14 Postganglionic Progressive AF 176 0.9 0.14 
15 Afferent Iatrogenic 176 4.2 2.0 
16 Afferent Iatrogenic 236 14.6 3.2 
Data in Parkinson's disease and amyloidosis are given as geometric means and range. AF =autonomic 
failure. iatrogenic= after radical neck dissection with preoperative irradiation. 
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Table ?.Renin and prorenin across the kidneys of patients with proliferative diabetic retinopathy and 
endstage nephropathy 
Sex female/male n 2/5 
Age median (range) yr 51 (41-60) 
Duration of diabetes median (range) yr 21 (7-38) 
Insulin treatment on insulin/not on insulin n 512 
Albuminuria mean (sd) gil 3.8 (0.8) 
Serum creatinine median (range) [.lmoVl 650 (311-730) 
Blood pressure systolic mean (sd) mmHg 179 (34) 
diastolic mean (sd) mmHg 94 (10) 
1311-hippurate clearance mean (sd) mUm in 61 (38) 
131!-hippurate extraction right kidney mean (sd) 0.38 (0.09) 
left kidney mean (sd) 0.30 (0.07) 
Renin right kidney artery geometric mean (range) mUll 9.4 (4.7-22.8) 
vein geometric mean (range) mUll 14.7 (8.2-27.7) 
vein/artery ratio mean (sd) 1.58 (028) 
Renin left kidney artery geometric mean (range) mUll 9.4 (4.8-21.7) 
vein geometric mean (range) mU/L 15.5(10.0-29.7) 
vein/artery ratio mean (sd) 1.69 (0.35) 
Pro renin right kidney artery geometric mean (range) mUll 464 (316-91 4) 
vein geometric mean (range) mUll 471 (330-982) 
vein/artery ratio mean (sd) 1.02 (0.06) ... 
Pro renin left kidney artery geometric mean (range) mUll 505 (308-896) 
vein geometric mean (range) mUll 526 (321-963) 
vein/artery ratio mean (sd) 1.04 (0.03) ... 
"'=no significant difference between right and left kidney. "'""=significantly different from 1.00, p < 0.001 
""""=not significantly different from 1.00 (no net secretion of prorenin). 
Statistical analysis. 
Differences between groups for discrete data were analyzed by CHI square test or by 
the Fisher exact test when appropriate. Differences lor continuous data were analyzed 
with the unpaired t-test or with the Student-Newman-Keuls test lor multiple comparisons. 
with the exception of the age of the patient and the duration of diabetes, which were 
analyzed with the median test (19). Renin and prorenin were not normally distributed. 
Logarithmic transformation yielded apparently normal distributions with similar standard 
deviations in all groups. These transformed values were used for statistical analysis. 
Multiple regression analysis was performed with the use of the SPSS/PC+ program 
1986 (SPSS Inc., Chicago, ILL, USA). 
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RESULTS 
Correlations of prorenin with diabetic complications. 
In Table 1 the patients are grouped according to the presence or absence of persistent 
proteinuria. The groups did not significantly differ in female/male ratio, age, HbA 1 c and 
systolic and diastolic pressure or in the prevalence of insulin treatment and neuropathy. 
The prevalence of diabetic retinopathy was higher in the group wtth persistent pro-
teinuria, and retinopathy in this group was more often of the proliferative type. Diabetes 
was of longer duration and serum creatinine was also higher in these patients. The 
plasma level of prorenin was nearty two times higher but renin was not significantly 
different. 
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Figure 1. Plasma prorenin in patients without diabetic retinopathy (NOOR), with background diabetic 
retinopathy (BGDR) or with proliferative diabetic retinopathy (PDR). The patients are subdivided 
in those with and without macroalbuminuria. Horizontal lines in-dicate geomatric means. 
Note the logarithmic scale. 
'=p<O.OS, "=p <0.01, "'=p<0.001, for difference from the group without diabetic retinopathy. 
t=P<0.05,'f=p<0.01, fordifferencefromthegroupwithbeckgrounddiabeticretinopathy.Hatched 
bar, normal range. 
In Table 2 the patients are grouped according to the presence or absence of 
microalbuminuria. Again the groups did not significantly differ in female/male ratio and 
HbA 1 c or in the prevalence of insulin treatment and neuropathy. There was also no 
difference in serum creatinine. Systolic blood pressure was higher in the patients with 
microalbuminuria than in those without albuminuria. In contrast with the data obtained 
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when the diabetics were grouped according to whether they had macroalbuminuria or 
not, no differences in the plasma levels of prorenin or renin were found between the 
patients with and without microalbuminuria. 
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Figure 1. Plasma prorenin in patients without diabetic retinopathy (NOOR), with background diabetic 
retinopathy (BGDR) or with proliferative diabetic retinopathy (PDR). The patients are subdivided 
in those with and without microalbuminuria. Horizontal lines indicate geomatric means. 
Note the logarithmic scale. 
"=p <0.05, """=p <0.01, *'""*=p-<0.001, for difference from the group without diabetic retinopathy. 
t~p<0.05,f~p<0.01, for difference from the group with background diabetic retinopathy.Hatched 
bar, normal range. 
Prorenin was higher in the patients with diabetic retinopathy than in those without 
retinopathy, and the levels were highest in those with proliferative diabetic retinopathy, 
no matter macro- or microalbuminuria was present or not (Fig.1 and 2). The mean level 
of prorenin was 2-3times normal in the patients with proliferative retinopathy but was not 
above normal in the patients without retinopathy, and this was the case both in the 
presence and absence of macro- or microalbuminuria. 
Reninin the patients with proliferative retinopathy was also higher than in those 
without retinopathy but the difference was much smaller than for prorenin and the 
difference was only seen in the group with macroalbuminuria. There was no difference 
in renin between the patients with background retinopathy and those without retinopathy, 
and this was true for the groups with macroalbuminuria or microalbuminuria as well as 
for the group without albuminuria. 
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The influence of various factors on the plasma level of prorenin was examined by 
multiple regression analysis (Tables 3-5). The factors studied were: sex, age, duration 
of diabetes, insulin treatment, blood glucose, HbA1c, systolic and diastolic blood 
pressure, neuropathy, serum creatinine, macroalbuminuria and, finally, retinopathy. 
Statistically significant correlations were found with sex, duration of diabetes, insulin 
treatment, serum creatinine, proteinuria and retinopathy. In case of neuropathy, prorenin 
was also generally increased but this finding was not statistically significant. 
The factors most strongly correlating with prorenin were insulin treatment. serum 
creatinine, macroalbuminuria and retinopathy. The correlation with creatinine was not 
linear and the term creatinine square was introduced in the regression equation (Table 
6). Once allowance was made for the presence of retinopathy, categorized as 
background diabetic retinopathy or proliferative diabetic retinopathy, the relations of 
prorenin with sex, duration of diabetes and insulin treatment were no longer significant. 
This can be explained by interrelations between the various factors. In 34 percent of 
males proteinuria was present as compared to 22 percent of females. Also, males had 
higher (p <0.001) creatinine levels than females. Finally with regard to the duration of 
diabetes, it appeared that longer duration generally implied insulin treatment and 
macroalbuminuria. 
The multiple regression analysis therefore shows that high prorenin was associated 
with nephropathy and retinopathy and that other factors did not significantly contribute 
to this association. The analysis further indicated that the association with retinopathy 
was, at least in part, independent of the association with nephropathy. In contrast with 
the findings on prorenin, no significant correlations were found between the plasma level 
of :enin and the various factors mentioned above. 
Plasma prorenin in non-diabetics with autonomic neuropathy. 
Supine plasma renin was below the normal range in two patients with a preganglionic 
lesion and in two with a postganglionic lesion. In none of the patients with autonomic 
neuropathy did plasma renin rise after headup tilt for 30 min, despite a blood pressure 
drop of 20-25 mm Hg systolic and 10-15 mmHg diastolic. Plasma prorenin was within 
the normal range in all patients (Table 6). 
Renal vein plasma prorenin in diabetics with advanced nephropathy. 
Arterial plasma prorenin was markedly elevated in these patients (Table 7). The renal 
vein-to-artery prorenin ratio was 1.02 (0.03) on the right side and 1.04 (0.03) on the left 
(mean,sd). In subjects with untreated essential hypertension {n=18) the ratio is 1.03 
(0.05) on the right side and 1.04 (0.06) on the left (20) . Thus the ratio in the diabetes 
was not higher than in subjects with essential hypertension, despite the markedly 
reduced renal plasma flow in the former. 
Peripheral vein renin in the diabetics was at the lower end of the normal range. 
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The renal vein-to-artery ratio of renin was 1.58 (0,28) on the right side and 1.69 (0,35) 
on the left. In subjects with untreated essential untreated essential hypertension the 
ratio is 1.28 ( 0.13) on the right side and 1 ,30 (0, 14) on the left (20). The higher ratio in 
the diabetics is a consequence of the lower renal perfusion. 
DISCUSSION 
Luetcher et al. (2) were the first to report that the plasma level of prorenin is increased 
in patients with longstanding diabetes and they suggest that prorenin might serve as a 
marker of microvascular disease. Our study offers further evidence in support of this. 
We found that in our patient population the elevated prorenin was associated with the 
presence of diabetic retinopathy, particularly the proliferative type, and that a number 
of confounding factors, i.e. sex, duration of diabetes, blood pressure, the blood levels 
of glucose and HbA1c or the prevalence of neuropathy or insulin treatment, did not 
significantly contribute to this association. 
In contrast with prorenin, plasma renin is normal or low in most diabetics (3,4). In the 
patients in whom proliferative diabetic retinopathy was associated with macroalbuminuria 
we found plasma renin to be somewhat higher than in the groups without these 
complications. Higher renin levels in diabetics with albuminuria have also been reported 
by others (21). This finding might be an artifarct caused by inadvertent activation of 
prorenin during blood sampling and processing. Samples from such patients contain 
relativily large quantities of prorenin and inadvertent cryoactivation of prorenin as little 
as one percent is already sufficient to raise the measured level of renin by 50% (16). 
Autonomic neuropathy is not uncommon in diabetes. Loss of adrenergic stimulation 
may lead to decreased secretion of renin by the juxtaglomerular cells and it has been 
postulated that a compensatory increase in the synthesis and secretion of prorenin by 
these cells is the cause of the increase in plasma prorenin in diabetes (8,9). However, 
our observations in nort-diabetics with autonomic neuropathy do not support this 
explartation. Our data demortstrate that autonomic neuropathy in the absence of 
diabetes and its complications does not cause plasma prorenin to rise to the levels that 
are found in diabetics, even when there is serious loss of adrenergic function. 
It is possible that, independently of the presence of autonomic neuropathy, the 
processing of prorenin to renin in the juxtaglomerular cells is somehow impaired and that 
the secretion of prorenin from these cells is increased when the kidney is affected by 
diabetic microvascular disease (7). 
The mean level of prorenin was not above normal in the patients without retinopathy 
both in the presence and absence of macro- ormicroalbuminuria, whereas the mean level 
of prorenin was markedly elevated in the patients with proliferative retinopathy, not 
only when retinopathy was associated with macro- or microalbuminuria but also when 
albuminuria was absent. These findings suggest that retinopathy is a more important 
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determinant of abnormally h"1gh prorenin than nephropathy. 
We measured the renal vein-to-artery ratio of pro renin in diabetics who had endstage 
nephropathy and in whom peripheral vein plasma prorenin was elevated. The ratio in 
these patients was not significantly different from unity (no net secretion) and was not 
higher than in essential hypertension, despite the fact that renal plasma flow was much 
lower. Thus, the high plasma level of prorenin in the diabetics could not be fully explained 
by abnormal secretion by the kidneys. 
This leaves us with two possibilities. One is reduced extrarenal clearance of prorenin 
and the other is increased extrarenal production. Non-enzymatic glycosylation of 
prorenin might lead to reduced clearance from the circulation. We found, however, no 
significant correlation between the levels of prorenin and HbA 1 c. It has been postulated 
that a cellular receptor exists, which binds the prosegment of prorenin (22). Such binding 
might initiate internalization of prorenin, for instance in the vascular endothelium. A 
number of endothelial functions is known to be impaired in diabetes (23-25) and this may 
also be true for prorenin internalization, with reduced clearance of prorenin from the 
circulation as a result. 
With regard to the possibility of increased production of prorenin at extrarenal sites, 
it is of interest that large amounts of (pro)renin have been found in highly vascularized 
extrarenal tumors (26,27). Neovascularization is an important feature of diabetic 
microvascular disease. In this context it might be relevant that the vitreous of the eye 
contains prorenin in concentrations that are, relative to albumin and other plasma 
proteins, much higher than in plasma (17). Prorenin is also present in extracts of the 
retina in concentrations too high to be explained by trapped plasma (28). It is also 
interesting that, for a given level of albumin, the level of proreni n in the vitreous from eyes 
with retinal detachment due to proliferative diabetic retinopathy was found to be higher 
than in eyes with spontaneous retinal detachment (17). It seems unlikely that the eye 
is an important source of circulating prorenin because of the small contribution of the eye 
to total body blood flow but extensive areas of microvascular disease, possibly 
associated with new vessel formation, elswhere in the body might produce enough 
prorenin to increase its level in plasma. 
AI any rate, the present study appears to indicate that the high plasma levels of prorenin 
found in diabetics are not an immediate consequence of altered glucose metabolism. 
These high levels are related to the development of microvascular disease in the eye 
and the kidney, and they are, at least in part, due to either decreased clearance of 
prorenin from the circulation or increased production at extrarenal sites or both. 
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Chapter3 
Summary 
Renin, prorenin and immunoreactive renin were present in vitreous and subretinalfluid 
of eyes from subjects with and without diabetic retinopathy. Renin substrate, albumin, 
transferrin and immunoglobulin G were also found in these ocular fluids. In many 
samples renin levels were close to the detection limit of the assay. The levels of renin 
substrate, albumin, transferrin and immunoglobulin G varied widely among ocular fluid 
samples, but in each individual sample the levels were, relative to each other, similar 
to those in plasma. in contrast, the pro renin level in ocularfluid was up to 1 OOtimes higher 
than expected on the basis oft he plasma protein content of ocular fluid. Moreover, there 
was little difference in prorenin ooncentrations between samples with a low and a high 
plasma protein content. Prorenin, relative to albumin and other plasma proteins, was 
higher in vitreous fluid from eyes with proliferative diabetic retinopathy complicated by 
traction retinal detachment than in eyes of non-diabetic subjects with spontaneous 
retinal detachment. It appears that prorenin (and possibly renin) in ocular fluid is 
oontrolled by an active and specific process, possibly local synthesis within the eye. 
In view ofthe vascular actions of angiotensin II, an intraocular renin-angiotensin system 
may play a role in diabetic retinopathy. 
Introduction 
The kidney secretes both renin and prorenin, an inactive precursor of renin, into the 
circulation. Plasma of nephrectomized patients oontains little or no renin but it does 
contain prorenin (1 ,2), in concentrations sometimes as high as those in normal 
individuals. It thus appears that extrarenal production can make a major contribution to 
the level of prorenin in plasma, whereas most, if not all, renin in plasma is secreted by 
the kidneys. Synthesis of renin or prorenin and other components of the renin-
angiotensin system is known to occur at various extrarenal sites, for instance adrenal 
(3,4) pituitary (3,4), testis (3,4), brain (5), and ovary (6-8). Cultured human chorionic 
cells (9) and ovarian thecal cells (8) release prorenin into the medium and there is good 
evidence that in women with hyperstimulated cycles and during pregnancy, the ovary, 
probably the corpus luteum, releases prorenin into plasma (7, 1 0). 
A common feature of the organs in which synthesis of renin or prorenin occurs is their 
extensive vascularization (11 ). The eye, particularly the retina and uveal tract, is such 
a highly vascularized organ. Angiotensin 11-binding sites have been found in retinal blood 
vessels (12), and transvitreal infusion of angiotensin I and II produces oonstriction of 
the retinal arteries (13). The retina oontains angiotensin converting enzyme activity (14) 
and this enzyme is also found in aqueous fluid (15). Here we report measurements of 
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renin, prorenin, immunoreactive renin, renin substrate and various plasma proteins in 
aqueous, vitreous and sub retinal fluid. The ocular fluid samples were obtained at the time 
of cataract extraction or vitrectomy and the protein concentrations in these samples 
were compared with those in simultaneously obtained plasma. Our study included eyes 
affected by proliferative diabetic retinopathy because the renin-angiotensin system has 
been implicated in neovascularization {16). 
Subjects and methods 
Non-diabetic subjects 
Aqueous fluid was collected at the time of cataract extraction from 21 subjects {15 
women and 6 men; mean age, 68 yr; range, 26-86 yr). Four subjects were receiving a 
diuretic and six a a-adrenergic antagonist. 
Vitreous fluid aspirates were obtained from 16 subjects (8 women and 8 men; mean 
age, 52 yr; range, 20-82 yr). The samples were collected at the time of pars plana 
vitrectomy, which was performed because of recurrent retinal detachment due to 
proliferative vitreoretinopathy. Four subjects were receiving a diuretic, in 3 of them 
combined with a a-adrenergic antagonist. 
Subretinal fluid was obtained from 18 subjects (8 women and 10 men; (mean age) 
59 yr; range, 8-76 yr), with rhegmatogenous retinal detachment, which is a type of retinal 
separation precipitated by a hole or a tear in the retina. In this type of detachment fluid 
accumulates between the retinal pigmentepitheliallayerandthe neural retina. The retinal 
detachments had occurred between 1 day and 3 months (median, one week) before 
subretinal fluid collection. Three subjects were receiving a diuretic, in 2 of them 
combined with a a-adrenergic antagonist. 
Diabetic subjects 
Vitreous fluid was obtained from 15 diabetic subjects with proliferative diabetic 
retinopathy (8 women and 7 men; mean age, 51 yr; range, 28-71 yr). Vitrectomy was 
performed because of traction retinal detachment. The duration of diabetes ranged from 
6-32 yr. Twelve subjects were receiving insulin, 5 were receiving a diuretic and 1 was 
receiving a a-adrenergic antagonist. 
Aqueous fluid can only be collected at the time of cataract extraction. In diabetic 
subjects, however, this procedure may stimulate proliferative retinopathy. Cataract 
extraction is therefore not performed in eyes affected by proliferative diabetic retinopathy. 
Consequently, aqueous fluid could not be collected from such eyes. We also were unable 
to collect subretinal fluid from diabetic subjects with traction retinal detachment because 
drainage of subretinal fluid is rarely performed in these subjects and, if it is performed, 
the approach is via the transvitreal route, so that the sample is heavily contaminated 
with material from the vitreous. 
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n subjects with a rhegmatogenous retinal detachment. subretinal fiuid is removed via the 
transscleral route, where no such contamination occurs. 
Collection of ocular fluid samples 
Approximately 0.1 mL aqueous fiuid was collected with a tuberculin syringe and a 25-
gauge needle. The needle was introduced atthe limbus ofthe co mea through the groove 
of the cataract incision. A 0.3-1.0 mL sample of vitreous fiuid was aspirated before 
substitution fluid was infused into the vitreous. Subretinal fluid was aspirated transsclerally, 
after local diathermic coagulation of the choroid. 
The ocular fiuid samples were free of macroscopically visible blood and were frozen 
at -70 °C immediately after collection. A peripheral venous blood sample was drawn 
simultaneously with the collection of ocular fluid. Blood for determination of renin. 
prorenin, immunoreactive renin, renin substrate, albumin, transferrin and immunoglobulin 
G (lgG) was collected in tubes containing 0.1 volume of 0.13 moi/L trisodium citrate. 
The blood was immediately centrifuged at 3000 x g for 10 minutes at room temperature, 
and 1-mL aliquots of plasma were stored at -70 oc. Blood for determination of angiotensin 
II was collected in prechilled tubes containing 0.1 volume of 0.06 mmoi/L pepstatin-A. 
0.125 moi/L disodium EDTA and 0.025 moi!L phenantroline in order to block renin, 
angiotensin converting enzyme and angiotensinases, respectively. The blood samples 
were immediately centrifuged at 3000 g for 10 minutes at 4 oc. and 2-mL aliquots of 
plasma were stored at -70 oc. 
Analytical methods 
Renin was measured in duplicate by enzyme-kinetic assay. in which the samples were 
incubated at 37 oc and pH 7.5 with saturating amounts of sheep renin substrate in the 
presence of inhibitors of angiotensinases and angiotensin converting enzyme. The 
generated angiotensin I was quantitated by RIA (17). For measuring pro renin in plasma. 
prorenin was converted into renin by incubation with Sepharose-bound trypsin (0.25 mg/ 
mL) for 48 hours at 4 oc. Previous studies. including measurements of total immuno-
reactive renin (renin plus prorenin). indicated that the prorenin to renin conversion in 
plasma is complete after incubation with the immobilized trypsin underthese circumstances 
and that destruction of renin orprorenin does not occur (18). Experiments in which known 
quantities of purified human kidney renin were added to ocular fluid demonstrated that 
in some samples destruction of renin did occur with this method. This destruction might 
be due to the low content of.serine protease inhibitors in ocular fluids as compared to 
plasma. Therefore, in ocular fluid we chose to use plasmin to convert prorenin into renin 
(17,19). Forth is purpose the sample was incubated with plasmin at a final concentration 
of 0.5 )lmoi/L for 48 hours at 4 °C before the assay. 
Comparison of the results of the enzyme-kinetic assay in plasmin-activated ocular 
fluid samples with the results ofthe assay of total immunoreactive renin in non-activated 
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samples demonstrated that the conversion by plasmin was complete without any loss 
of prorenin or renin; the specific enzymatic activity of plasmin-activated prorenin in 
ocular fluid samples was not different from the specific activity of purified kidney renin 
and plasma renin (see Results). Plasmin at the concentration mentioned above cannot 
be used to activate prorenin in native whole plasma because of its high content of 
plasmin inhibitors. 
The concentrations of renin and prorenin measured by the enzyme-kinetic assay were 
expressed as milliunits per L using the WHO human kidney renin standard 68/356 (WHO 
International Laboratory for Biological Standards, London, United Kingdom) as reference 
standard. The lower limit of detection was 0.5 mU/L and the interassay variability at low 
concentrations of renin or prorenin (2-5 mU/L) was 11 %for both renin and prorenin. 
Immunoreactive renin was measured in duplicate with a sandwich assay (18.20) using 
the monoclonal antibodies R 3-27-6 and R 3-36-16 (Ciba-Geigy, Basel. Switzerland). The 
two monoclonal antibodies recognize different epitopes ofthe renin molecule and react 
equally well with human kidney renin and chorionic cell culture prorenin. The assay was 
carried out in polystyrene tubes (Star Tubes, code4-70319; Nunc, Roskilde, Denmark). 
The inner surface ofthesetubes was coated with antibody R 3-27-6 (21 ).Immunoreactive 
renin in the assay sample is quantitatively bound to this antibody. The amount of solid 
phase-bound immunoreactive renin was measured with antibody R 3-36-16, which had 
been radiolabeled with 1251. The results of this assay were expressed as nanograms 
per L using highly purified human kidney renin (Ciba-Geigy) as a standard. One milliunit 
of the WHO human kidney renin standard corresponded to 1.41 ng of the Ciba-Geigy 
standard. The lower limit of detection was 5 ng/L, and the interassay variability was 8%. 
The concentration of renin substrate was determined as the maximum quantity of 
angiotensin I that was generated during incubation at 37 iC and pH 7.5 with an excess 
of purified active human kidney renin in the presence of inhibitors of angiotensinases and 
angiotensin converting enzyme (18). The lower limit of detection was 1 nmoi!L and the 
interassay variability was 10 %. 
Immunoreactive angiotensin II was measured by radioimmunoassay after SepPak 
(Waters, Milford, MA, USA) extraction of the sample (22). The lower limit of detection 
was 2 pmoi/L and the interassay variability was 15%. 
Albumin, transferrin and lgG were measured by single radial immunodiffusion (LC and 
NOR-Partigen plates, Behringwerke, Marburg, Germany) according to the method of 
Mancini et al (23). 
Data analysis 
Plasma proteins enter the vitreous mainly by diffusion. One of the reasons why the 
concentrations of these proteins are low in vitreous fluid is that they have to cross a 
relatively impermeable barrier. Breakdown oflhis so-called blood-retinal banrierleads to 
increased diffusion of plasma proteins into the eye. The rate of diffusion of a given protein 
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is related to its molecular size and plasma concentration. In accordance with this is the 
fact that the concentrations of the different proteins relative to each other are similar in 
plasma and vitreous fluid {24,25). 
Thus, unless certain specific uptake processes exist, for which in the eye no 
evidence is available with regard to any of the proteins mentioned in this paper, one would 
expect a relatively high intraocular albumin concentration (due to partial breakdown of 
the blood-retinal barrier) to be accompanied by a proportionally high concentration of 
plasma proteins of comparable size. Therefore, we chose to take the vitreous fluid/ 
plasma concentration ratio of albumin as an index of the integrity of the blood-retinal 
barrier, an abnormally high ratio being an indication of breakdown of this barrier. By 
multiplying this ratio with the level of a given protein in plasma, the level of this protein 
in ocular fluid can be estimated, assuming that, as mentioned above, this protein is 
transferred from the blood into the vitreous and vice versa by mechanisms that are 
qualitatively and quantitatively the same as those for the transfer of albumin. For 
example, for renin substrate the calculation would be as follows: 
[RSoJ = [RS,J X [ALB.,]/[ALB,J, 
in which RS is renin substrate, ALB is albumin, oc is ocular fluid, pi is plasma, and 
brackets denote the concentration. 
If our assumptions are correct, the calculated concentrations should be equal or at least 
closely correlated to the actually measured concentrations. Therefore, the two sets of 
data were analyzed by linear regression. 
For analyzing differences between diabetic and nondiabetic subjects unpaired !-tests 
were performed after logarithmic transformation of the data. 
Values were considered significant if p < 0.05. 
Results 
Non-diabetic subjects 
The levels of renin in many vitreous and aqueous fluid samples were at or below the 
detection limit of the assay (0.5 mUlL), which is less than 5% of the level in plasma. 
In subretinal fluid the renin level was about 20 %of that in plasma (Table 1 ). Prorenin 
was detectable in all samples of vitreous and aqueous fluid; its level in vitreous fluid was 
about 20 % and in aqueous fluid about 5 % of that in plasma. In subretinal fluid the 
prorenin level was as high as in plasma. Renin and prorenin concentrations in the fluid 
compartments of the eye were in the order: subretinal fluid> vitreous fluid > aqueous 
fluid. The levels of renin substrate in subretinal, vitreous and aqueous fluid were 10, 5 
and 0.5 %of those in plasma, respectively. Thus, they too were in the order: subretinal 
fluid > vitreous fluid > aqueous fluid. This was also true for the levels of albumin, 
transferrin and lgG (Table 2). There was no correlation between the levels in ocular fluid 
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and those in plasma for any of the proteins. 
As described under Data analysis above, a theoretical concentration in ocular fluid 
for each protein was predicted based on the albumin content of the sample. 
For renin substrate, transferrin and lgG the calculated and measured values were linearly 
correlated in both vitreous and subretinal fluid, and the slopes of these correlation lines 
were not significantly different from 1.0 (Tables 3 and 4). Renin substrate and transferrin 
concentrations in ocular fluid could, in fact, be accurately predicted by these calculations. 
The lgG level measured was systematically about 2 times lower than that calculated, 
which may be due, at least in part, to its larger molecular size as compared to that of 
albumin and the other proteins. 
For prorenin the findings were different. The prorenin levels in both vitreous and 
subretinallluid varied much less than the levels of the other proteins (Tables 1 and 2). 
Furthermore, calculating prorenin concentrations on the basis of the albumin content of 
the sample yielded much lower (down to 1/100th) values than those actually measured, 
particularly in samples with a low plasma protein content (Intact blood-retinal barrier). 
The prorenin level in subretinallluid was higher than that in vitreous fluid, even when 
corrections were made for the higher plasma protein content in subretinal fluid samples 
(Fig. 1). In both vitreous and sub retinal fluid the slopes of the regression lines describing 
the correlation between the measured and calculated prorenin concentrations were 
significantly different from 1.0, thereby indicating the different behavior of prorenin as 
compared to albumin and other plasma proteins. 
Table 1. Levels of prorenin, renin, and renin substrate in ocular fluids. 
Prorenin (mUll) Renin (mUll) Renin substrate (nmoVL) 
n 
Eye Plasma Eye Plasma Eye Plasma 
Non-diabetic subjects 
Aqueous vs. plasma 21 4.4 163 <0.5 9.8 5.1 1080 
2.0-8.7 36.7-453 ND-Q.S 1.5-62.9 1.6-15.4 898-1430 
Vitreous vs. plasma 16 34.5 174 <1.0 17.3 54.5 1120 
17.4-<51.9 67.0-396 ND-2.8 3.7-51.0 3.0-830 791-3030 
Subretinal vs. plasma 18 132 128 2.4 14.3 107 1230 
36.8-305 65.1-251 0.9-6.4 4.3-105 10-1430 841-2250 
Diabetic subjects 
Vrtreous vs. plasma 15 61.0 357 <2.0 17.7 61.0 1030 
19.0-172 121-<>79 ND-3.5 4.4-127 7.0-1000 628-2040 
Shown are the geometric mean and range. NO, Not detectable.Jn vitreous fluid and plasma the levels of 
prorenin, but not those of renin substrate. were higher in diabetic than in non-diabetic subjects (p < 0.01). 
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Table 2. Levels of albumin: lgG, and transferrin in ocular fluids. 
Albumin (giL) lgG (giL) Transferrin (giL) 
n 
Eye PO.sma Eye PO.sma Eye PO!sma 
Non-diabetic subjects 
Aqueous vs. plasma 21 0.19 33.1 NO NO NO NO 
0.06-0.45 28.3-39.4 
Vitreous vs. plasma 16 1.55 33.0 0.19 11.0 0.18 2.44 
0.11-20.2 22.9-42.5 0.03-0.70 6.61-14.4 0.02-1.7 4 1.60-2.99 
Subretinal vs. plasma 18 3.03 35.4 0.48 11.2 0.45 2.57 
0.39-28.5 292-41.9 0.07-5.10 7.G-18.2 0.06-3.97 2.08-3.44 
Diabetic subjects 
Vitreous vs. plasma 15 1.51 29.2 0.19 9.2 0.14 2.06 
0.32-17.1 21.7-36.8 0.04-0.96 3.88-16.7 0.06-0.37 1.5G-2.70 
Shown are the geometric mean and range. The levels of albumin, lgG, and transferrin in both vitreous and 
plasma did not differ between diabetic and non-diabetic subjects. NO, Not done. 
The data on prorenin shown in Tables 1, 3 and 4 and Figs. 1-3 were obtained by the 
enzyme-kinetic assay. That prorenin measured by this assay is, in fact, prorenin is 
supported by the excellent agreement with the measurements of immunoreactive renin 
(Fig. 4). The mean specific enzymatic activity of in vitro activated prorenin was 0.7 ± 
0.2 (± SD) mU/ng (n=9) in vitreous fluid and 0.6 ± 0.2 mU/ng (n=1 0) in sub retinal fluid. 
These values are not different from the specific activity of renin from plasma and kidney 
(18). 
Immunoreactive angiotensin II was 11.1 ± 1.8 pmoi/L in vitreous fluid (n=12) compared 
to 17.5 ± 1.3 pmoi/L in plasma. In subretinal fluid (n=15) it was 14.8 ± 1.6 pmoi/L 
compared to 23.9 ± 2.0 pmoi!L in plasma. 
55 
AQUEOUS 
FLUID 
VITREOUS 
FLUID 
SUBRETINAL 
FLUID 
mU/g~------------1--------------~-------------1 
60 
50 
40 
30 
20 
1 0 
0 
L::::J plasma ~ocular fluid 
Figure 1. Mean (SE) proreninlalbumin concentration ratio in ocular fluids and plasma of nondiabetic 
patients. 
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Figure 2. Measured versus calculated concentrations of prorenin (top panel) and renin substrate (bot-
tom panel) in vitreous fluid. For an explanation ofthecalculation see text (Data analysis). The 
slopes and significance levels of the correlations are given in Table 3. o diabetic, e non~ 
diabetic. 
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Figure 3. Measured versus calculated concentrations of prorenin (top panel) and renin substrate (bot~ 
tom panel) in subretinal fluid. For an explanation of the calculation see text (Data analysis). 
The slopes and significance levels of the correlations are given in Table 4. 
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Table 3. Correlations between the measured and calculated concentrations of proteins 
in vitreous fluid. 
Protein 
Pro renin 
Non-diabetic subjects 
Diabetic subjects 
Renin substrate 
lgG 
Transferrin 
Regression Line 
y = 0.015"x + 1.523 
y = 0.328"x + 1.370 
y = 1.024x - 0.028 
y = 1.063x - 0.344 
y = 0.899x + 0.066 
r 
0.05 
0.64 
0.97 
0.91 
0.89 
p 
NS 
< 0.05 
< 0.0001 
< 0.0001 
< 0.0001 
y is the log (measured concentration); xis the log (calculated concentration). For renin 
substrate. lgG. and transferrin. data from diabetic and nondiabetic subjects were 
combined because no differences were found for these proteins between the two groups 
(Tables 1 and 2). 
"Slope different from 1.0. p < 0.0001. 
Table 4. Correlations between the measured and calculated concentrations of proteins 
in subretinal fluid. 
Protein Regression Line r p 
Pro renin y = 0.271•x + 1.839 0.61 < 0.01 
Renin substrate y = 0.975x + 0.064 0.98 < 0.0001 
lgG y = 0.941x- 0.302 0.99 < 0.0001 
Transferrin y = 0.934x + 0.262 0.94 < 0.0001 
y is the log (measured concentration); x is the log (calculated concentration). 
"Slope different from 1.0. p < 0.0001. 
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Diabetic subjects 
The results of the renin substrate, albumin, transferrin, and lgG measurements in 
vitreous fluid and plasma ofthediabeticsubjects were similar to those in the non-diabetic 
subjects (Tables 1 and 2). The levels of renin and prorenin in vitreous fluid were higher 
in the diabetic than in the non-diabetic subjects. Prorenin was also higher when 
allowance was made for differences in plasma protein content of the samples. In the 
diabetic subjects the prorenin concentration of vitreous fluid correlated with the plasma 
prorenin concentration (r-=0.78, n=15, p < 0.001 ). In the non-diabetic subjects there was 
no significant correlation between the levels of prorenin in vitreous fluid and plasma. 
As in the non-diabetic subjects, prorenin in vitreous samples with low plasma protein 
content was much higher (up to 25 times) than expected on the basis of the albumin 
content of the samples. 
Immunoreactive angiotensin II was 9.0 ± 2.5 pmoi/L in vitreous fluid (n=15) compared 
to 9.9 ± 2.9 pmoi/L in plasma. 
lmmuno- 3000 
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• 
.. 
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1 00 .... 
• 30 .. 
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1 3 10 30 100 300 1000 3000 
Renin plus prorenin (Enzyme-kinetic assay) mU/L 
Figure 4. Total renin (pro renin plus renin) measured by enzyme-kinetic assay versus immunoreactive 
renin (r=0.97, p <0.0001). o plasma, Ill subretinal fluid, e v~reous fluid,£ aqueous fluid,+ WHO 
human kidney renin standard. 
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Discussion 
The levels of albumin (mol wl, 69 K), transferrin (mol wl, 90 K), lgG (molwt, 150 K) and 
renin substrate (mol wl, 65 K) in vitreous fluid differed widely from sample to sample, but 
in each individual sample the levels were, relative to each other, comparable to those 
in plasma. The lgG level in vitreous fluid, relative to that of albumin, was systematically 
somewhat lower than in plasma, probably due to its larger molecular size (25). These 
results are in agreement with earlier findings that most soluble protein in the vitreous is 
derived from plasma (24-26). 
The plasma protein content of normal vitreous fluid has been estimated to be 0.5-2% 
of that in plasma (25,26). In our study vitreous fluid from eyes with recurrent retinal 
detachment due to proliferative vitreoretinopathy contained higher levels of plasma 
proteins. These higher values probably reflect partial breakdown of the blood-retinal 
barrier in such eyes (27). 
The blood-retinal barrier is formed by the tight junctions between the endothelial cells of 
the retinal capillaries and the tight junctions between the retinal pigment epithelial cells, 
the latter restricting the transfer of plasma proteins escaping from the capillaries of the 
choroid (28). Proteins from plasma may enter the vitreous as a result of focal cellular 
necrosis, opening of the intercellular junctions, or vesicular transport and formation of 
transcellular channels. The rate of diffusion of proteins through such discontinuities in 
the blood-retinal barrier depends upon the concentration gradient across this barrier, the 
molecular size of the proteins and the number and area of discontinuities. Our results 
are in accordance with the contention that diffusion through these pores is the main 
mechanism of transfer of plasma proteins to the vitreous. 
This process, however, does not appear to hold true for prorenin (mol wt, 54 K). The 
concentration of prorenin, relative to that of albumin, was much higher in vitreous fluid 
than in plasma, and the prorenin level in vitreous fluid also was little influenced by its 
plasma protein content. Thus, prorenin may enter the vitreous by a mechanism that is 
different from that of albumin and other plasma proteins. This mechanism is selective 
for prorenin and may involve an active process. Receptor-mediated transcellular 
transport is such a selective mechanism, but as yet there is no evidence for the 
existence of cell-membrane receptors of prorenin. Our findings raise the possibility that 
not all the pro renin in the vitreous is derived from plasma but that some of it is produced 
in the eye. 
As described under Data analysis above, the vitreous level of prorenin that has crossed 
the blood-retinal barrier by passive diffusion in the same way as albumin can be 
estimated by multiplying the vitreous/plasma concentration ratio of albumin by the 
plasma prorenin level. By subtracting this calculated level of plasma-derived prorenin 
from the level actually measured, we estimated the level of prorenin that entered the 
vitreous by some process that is different from diffusion out of the circulation. In most 
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samples of vitreous fluid the estimated level of prorenin that had entered the vitreous by 
such a diffusion-independent process was more than 4 times higher than the estimated 
level of prorenin that had entered the vitreous by passive diffusion from blood. Thus, 
relative to the total amount of pro renin in vitreous fluid, the contribution of plasma-derived 
prorenin crossing the blood-retinal barrier merely by diffusion appears to be small. The 
implicit assumption underlying these calculations is that albumin and prorenin leave the 
vitreous in the same way, that is by free diffusion into the aqueous fluid (29), where the 
concentrations of these proteins were much lower than in the vitreous. 
The concentrations of albumin, transferrin, lgG and renin substrate were2-3times higher 
in subretinal fluid than in vitreous fluid. This was to be expected, since subretinal fluid 
from eyes with retinal detachment is more or Jess a concentrate of vitreous fluid (27). 
Vitreous fluid enters the subretinal space through the hole(s) of the retina, and water is 
actively absorbed from the sub retinal space by the retinal pigment epithelium. Again, the 
findings for prorenin were different. The concentration of prorenin, relative to albumin, 
was much higher in subretinal fluid than in plasma, particulany in subretinal samples with 
low plasma protein concentrations. Moreover, relative to albumin and other plasma 
proteins, prorenin was 2 times higher in subretinal than in vitreous fluid. If it is assumed, 
on the basis of the evidence discussed above, that most of the prorenin in the vitreous 
is not derived from plasma but is produced in the eye, the difference in pro renin content 
between subretinal and vitreous fluid may suggest that the subretinal compartment is 
closer to the site of prorenin production. 
Not only were the prorenin concentrations of vitreous and subretinal fluid higher than 
expected, so too were the renin (mol wt, 48 K) concentrations. The data on renin, 
however, are more difficult to interpret than those on prorenin because in many samples 
renin was at or below the detection limit of the assay and because some prorenin to renin 
conversion may have occurred during storage and handling of the samples. Even as little 
as 1 % conversion will result in a large percentage increase of renin in these samples. 
Immunoreactive angiotensin II also was found in samples of vitreous fluid, in 
concentrations comparable to those in plasma. Further work is needed to answer the 
question of its origin. 
That the levels of albumin and lgG in vitreous fluid from eyes affected by proliferative 
diabetic retinopathy were higher than the levels in normal eyes can be explained by the 
increased permeability of the blood-retinal barrier in this condition (30). 
The higher vitreous level of prorenin, relative to those of albumin and other plasma 
proteins, in the diabetic subjects as compared to non-diabetic subjects is more difficult 
to explain. The same arguments in favor ofthe hypothesis that, generally, diffusion from 
the blood contributes little to the total amount of prorenin in the vitreous, apply to both 
diabetic and non-diabetic subjects. It seems, therefore, unlikely that the higher level of 
prorenin in vitreous fluid of the diabetic subjects (2 times that in non-diabetic subjects) 
was caused by the higher level in plasma (also 2 times that in non-diabetic subjects). 
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It might be the other way around; increased release or leakage of pro renin from the eye 
affected by proliferative diabetic retinopathy may contribute to the increased prorenin 
level in plasma. 
This possibility is further supported by the finding that, in contrast with other proteins, 
the plasma concentration of prorenin in diabetic subjects correlated significantly with the 
concomitant vitreous prorenin concentration. Considering the fact that in some diabetic 
subjects the blood-retinal barrier for plasma proteins was still relatively intact (low 
vitreous/plasma albumin concentration ratio), whereas in others it was extremely leaky, 
no such correlation was to be expected, if diffusion from plasma into the vitreous was 
the main mechanism of transfer of prorenin. 
An elevated plasma prorenin level in diabetic subjects has been found to be associated 
with microvascular complications, including retinopathy (31). Evidence is accumulating 
that neovascularization is initiated by diffusible chemical factors arising from ischemic 
areas ofthe retina (32). Renin and angiotensin have been found in cultured neuronal and 
glial cells from rat brain (33,34); both cell types are abundantly present in the retina. 
Angiotensin II acts on vascular tone and has mitogenic and trophic actions on vascular 
smooth muscle and other cells (35). In fact, it has been reported to promote 
neovascularization (16). An intraocular renin-angiotensin system may, therefore, play a 
role in proliferative diabetic retinopathy. 
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Chapter4 
THE EFFECT OF PANRETINAL PHOTOCOAGULATION ON PLASMA PRORENIN 
IN DIABETIC PATIENTS WITH PROLIFERATIVE RETINOPATHY. 
Summary 
There is strong evidence for the presence of a local renin-angiotensin system in the eye. 
Plasma prorenin is abnormally elevated in diabetic patients, particularly when diabetes 
is complicated by proliferative retinopathy. In view of the angiogenic properties of Ang 
II a local RAS may be involved in the development of diabetic retinopathy and part of 
the elevated plasma prorenin might be derived from the eye. Panretinal photocoagulation 
leads to regression of ocular neovascularization. 
We studied the effect of photocoagulation on plasma prorenin levels in 12 diabetic 
patients with untreated proliferalive retinopathy. Before treatment plasma prorenin 
ranged from 236 mUll to 901 mUll with a geometric mean of 442 mUll, which is more than 
two times higher than in normals. 
Although, the mean plasma prorenin declined significantly four weeks after the last 
lasertreatment, no uniform effect on plasma prorenin was shown. 
In scme patients plasma prorenin remained unchanged, in others it declined, however 
in most patients prorenin did not become normal. 
Therefore no definite conclusion can be made regarding the effect of panretinal 
photocoagulation on plasma prorenin levels. 
It is unlikely that leakage of prorenin into the circulation from eyes affected with 
proliferative retinopathy has a major contribution to the high plasma prorenin level. In 
view of the low ocular plasma flow and the relative long half life of prorenin, high levels 
of prorenin are to be expected in the ocular compartments. However, such high levels 
have not been measured in vitreous fluid from eyes with proliferative retinopathy. The 
high plasma prorenin is probably to be explained by a decreased clearance from the 
circlution or by increased production from renal or other than ocular extrarenal sites or 
by both. 
Introduction 
Diabetic retinopathy is a major cause of blindness and visual morbidity in the Western 
world. Two ofthe severe blinding complications in diabetes are macular oedema and the 
development of neovascularization. 
The mechanism by which neovascularization develops is not known. However, there is 
a strong indication that retinal hypoxia may lead to proliferative retinopathy (1·3). 
Evidence is accumulating that diffusible chemical factors from ischaemic areas are 
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involved in this process (4). 
Diabetes mellitus is frequently accompanied by specific abnormalities of the renin-
angiotensin system (RAS). Prorenin, the inactive precursor of renin, is elevated in 
plasma of patients with longstanding diabetes with microvascular complications, such 
as nephropathy and retinopathy (5). Recent data showed an association between high 
plasma prorenin and the presence of proliferative retinopathy, independent of age, sex, 
insulin-dependency, metabolic control, neuropathy and, at least in part, independent of 
the presence of nephropathy as manifested by albuminuria (6). 
There is substantial evidence for the presence of a local renin-angiotensin system 
in the eye. This evidence is based on measurements of renin and prorenin in vitreous 
fluid and other ocular fluid compartments in diabetics and non-diabetics (7) and on 
immunohistochemical studies(B). Recent data from Wagner et al (9) demonstrated 
expression of renin, angiotensinogen and angiotensin-converting-enzyme mRNAs in 
human eyes. 
Theoretically, one could speculate that part ofthe elevated prorenin in plasma in patients 
with proliferative retinopathy might be derived from the eye. 
Angiotensin II has mitogenic and angiogenic properties (1 0-13) and because of these 
vascular actions, a local renin-angiotensin system in the eye may be involved in the 
pathogenesis of diabetic retinopathy. 
Panretinal photocoagulation has been demonstrated to markedly reduce the risk of 
severe visual loss by regression of neovascularization (14-16). 
The mechanism by which panretinal photocoagulation has this effect is not known. 
Regression of the new vessel formation is not only achieved by destruction of the area 
of neovascularization itself, but often also by destruction of non-related retinal areas with 
capillary non-perfusion. Some studies have shown that panretinal photocoagulation 
improves the oxygen supply to the inner retina by destroying the outer retina so that 
choroidal oxygen flux can reverse inner retinal hypoxia and the production of the putative 
vasoproliferative factor is stopped (17-20). In other words panretinal photocoagulation 
may work by eliminating the source of the angiogenic factor. 
If renin or other components of the RAS are involved in this proces, and if part of the 
elevated prorenin in plasma of patients with proliferative retinopathy originates from the 
eye, what is the effect of panretinal photocoagulation on the plasma level of prorenin 
in such patients. 
Subjects and methods 
We examined 265 diabetic (type I and 2) patients attending our outpatient facilities in 
eight consecutive months. Patients with overt cardiac failure, hepatic disease or renal 
failure (serum creatinin 200 umol/1 or above) were not included. Diabetic retinopathy was 
assessed by direct and indirect ophthalmoscopy after pupillary dilatation. 
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Retinopathy was categorized as background retinopathy (BGDR) or proliferative 
retinopathy (PDR). Previous photocoagulation (date, argon versus xenon, focal versus 
panretinal) and previous vitrectomy were noted. 
Blood was taken to measure serum creatinine, blood glucose, glycosylated hemoglobin 
and plasma renin and prorenin. Blood samples for renin and prorenin were drawn from 
an anticubal vein afterthe patients had been rested lor 30 minutes in the sitting position. 
In patients, undergoing photocoagulation treatment, samples of renin and prorenin were 
taken one day before, one day after, one week after and 4 weeks after each 
photocoagulation session. 
Non-timed overnight urine collections were obtained at two different days and were 
tested for the presence of albuminuria by dipstick method. Macroalbuminuria was 
defined as albumin above 250 mg/1 in each of the two samples, which is the detection 
limit of the dipstick method. In patients in which the dipstick test was negative, three 24 
hour urine collections were assessed lor microalbuminuria. 
From the group of patients with proliferative retinopathy (n=84) 22 patients had not 
been treated before and needed extensive pan retinal photocoagulation. In these patients 
we studied the effect of laser treatment on the levels of plasma prorenin and renin. 
Fluorescein angiography was performed to assess the presence of capillary non-
perfusion. These patients had intraretinal or preretinal new vessels with fibrosis on or 
within 1 disc diameter of the optic disc in both eyes. The patients were graded as having 
high-risk characteristics according to The Diabetic Retinopathy Study Research Group 
classification (15), and required extensive panretinal photocoagulation treatment. 
There were no substantial lens opacities or vitreous hemorrhages sufficient to interfere 
with laser treatment. Since treatment of patients with such high-risks cannot be 
postponed, it was not possible to study a matched control group orto randomize between 
direct or postponed treatment. Panretinal blue argon laser photocoagulation was 
performed with the Goldman three mirror lens or with the Rodenstock panfunduscope in 
1-3 sessions per eye within a period of 3-12 weeks. All four quadrants of each eye were 
treated. The area between the temporal arcades was spared. 
Laser parameters were: coagulation time between 0.1 and 0.3 sec., energy 0.2 to 0.8 
Watt, spotsize 500 um lor the Goldmann three mirror lens and 200 um lor the Rodenstock 
panlundoscope. The intensity was such that a slight blanching was visible. Two eyes 
had also a transconjuctival equatorial cryocoagulation treatment of the retina. 
Analytical procedures 
The plasma levels of renin and prorenin were measured with the enzyme-kinetic assay, 
in which the angiotensin I generated by plasma in vitro was quantified by 
radioimmunoassay. Priorto assay prorenin was converted to renin at4°C by immobilized 
trypsin in the presence of human serum albumin (21 ,22). Normal levels (79 non-diabetic 
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males, 81 non-diabetic females, age 48 + 15 yr, mean ;SO) of renin and pro renin were 
14.5 (3.6-61.4) and 154 (4.1-358) mU~ respectively (geometric mean and 95% confidence 
interval). 
Macroalbuminuria was assessed in non-timed overnight urine samples with dipsticx 
(Aibustix, Miles, Naperville, ILL, USA), which has a detection limit of 250 mg/1. 
Macroalbuminuria was defined as dip-stick positive or biuret reaction of protein above 
250 mg~ in two out of two overnight urine samples. Microalbuminuria was assessed in 
three consecutive 24 hour urine collections with radial immunodiffusion (23). The lower 
limit of detection was 2mg~ and the interassay variability was 8 %. Microal buminuria was 
defined as albuminuria of of 30-300 mg/24h in at least two of 24 hour urine collections. 
Statistics 
Data on plasma prorenin and renin from the group of 223 consecutive patients were 
compared by the Mann-Whitney U test. 
Data on plasma prorenin and renin from the group of untreated patients with PDR before 
and after panretinal photocoagulation were compared with the One-way analysis of 
variance for repeated measurements. 
Results 
From the group of 265 consecutive diabetics 84 patients had proliferative retinopathy. 
In this group 62 patients had been treated with photocoagulation in the past and 9 patients 
had undergone a vitrectomy. In this group of 62 patients there were 44 males, mean age 
was 53 years and mean duration of diabetes was 17 years. In 15 patients the diabetes 
was treated with oral medication only. 
Plasma prorenin in patients with proliferative retinopathy ranged from 75-2133 mU/1 with 
a geometric mean ol400mU~ , which is more than two times higher than in normal 
persons. Plasma renin ranged from 4.2-53.3 with a geometric mean of 15.8 mU/1, which 
is not different from the normal range. 
Out of the 84 patients with proliferative retinopathy 22 patients had not been treated 
before and they, according to the stage of their proliferative eye disease, required 
panretinal photocoagulation in both eyes. In these patients, after informed consent, the 
elect of panretinal photocoagulation on plasma prorenin were studied. Three patients 
became blind in one eye and were excluded because of the fact that they could not be 
treated in both eyes. Seven patients d'1d not complete the study or were exluded for 
several reasons. One patient moved to another country, two patients developed 
detoriation of the renal function (serum creatinine above 200 umol/1), three patients were 
put on ACE-inhibitor therapy bytheirown physician and one patient did not complete the 
photocoagulation therapy. 
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Twelve patients completed the study and their clinical data are shown in Table 1. The 
female-male ratio was 9 to 3. The age ranged between 23-76 years with a mean of 52 
years. All but three patients were treated with insulin. The duration of the diabetes ranged 
from 3-40 years with a mean of 20 years. Four patients were treated with diuretics and 
1 patient with a beta blocker and 1 patient with a alpha and beta blocker because of 
coexisting hypertension. The hypertension was well controlled and antihypertensive 
therapy was not changed during the study period. 
Six patients showed albuminuria (5 macroalbuminuria and 1 microalbuminuria) as a sign 
of diabetic nephropathy. 
Table 1. Clinical characteristics of diabetic patients with untreated eroflferative retinopathy 
oatient sex age durat"1on treatment serum albuminuria treatment 
of diabetes of creatinine of 
yr yr yr diabetes ~moi/L mg/24h hyt2ertension 
m 63 3 glibenclamide 102 12 furosemide 
2 m 49 21 insulin 200 >300 furosemide 
3 m 61 40 glibenclamide 139 >300 metoprolol 
4 m 64 16 insulin 115 17 furosemide 
5 m 37 23 insulin 95 >300 
6 m 45 25 glibenclamide 148 >300 labeto!ol 
7 f 75 17 insulin 80 5 
8 23 18 insulin 73 25 
9 28 11 insulin 63 5 
10 m 44 16 insulin 184 >300 
11 f 55 25 insulin 82 30 
12 m 76 22 insulin 166 25 
Table 2 and Rgure 1 show the plasma levels of prorenin and renin before treatment, one 
week after the first coagulation session and four weeks after the last session. Plasma 
prorenin before treatment ranged from 236 mUll to 901 mUll with a geometric mean of 
442 mUll, ,plasma renin ranged from 3.7-40.6 mUll with a geometric mean of 16.3 mU/ 
Plasma prorenin and renin was not changed the day after the coagulation session. Mean 
plasma prorenin decreased significantly from 442 U/ml to 302 uU/1 four weeks after the 
last lasertreatment. Mean plasma renin did not change significantly during folluw-up. It 
should be noted that in 6 patients no decrease in plasma prorenin could be demonstrated. 
In 5 out of 6 patients in whom plasma prorenin decreased, plasma prorenin remained 
above the normal range. 
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Table 2. 
patient 
' 2 
3 
' 5 
6 
7 
8 
9 
" 
" 
" 
Plasma prorenJn and remn before anct alter panretmal photocoagulation 
before 
treatment 
m 
90, 
457 
360 
447 
4" 
300 
582 
236 
4W 
458 
334 
Prorenin (mU[Ll Renin (mU[LJ 
one week alter tour weeks atter before one week attar 
first laser treatment last laser treatment treatment first laser treatment 
598 283 27.6 23.6 
mo 427 29.2 20.1 
370 23' 39.7 12.8 
346 352 40.6 24.4 
506 .,5 21.0 27.8 
428 480 3.7 6.5 
"' 
230 10.9 16.6 
402 505 43.3 19.6 
'" 
203 5., 6.7 
272 m 7.2 4.8 
320 2" 17.6 10.2 
430 463 8.5 14.8 
mUlL 1000 PRORENIN 
"' 
RENIN 
before 1 week after 
treatment first treatment 
4 weeks after 
last treatment 
tour weeks attar 
last laser treatment 
15.3 
16.1 
16.2 
385 
20.4 
9.4 
10.3 
23.8 
5.5 
4.0 
5.6 
22.1 
Rgure 1. The effect of pan retinal photocoagulation on plasma prorenin and renin levels in 12 patients with 
proliferative diabetic retinopathy. 
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Discussion 
There is strong evidence for the presence of a local renin-angiotensin system in the eye. 
In view of the angiogenic and mitogenic vascular actions of angiotensin II, the most 
important biologically active end product oflhe renin-angiotensin sytem, it is conceivable 
that a local renin-angiotensin system in the eye is involved in the development of diabetic 
proliferative retinopathy. The vitreous fluid from eyes affected by proliferative diabetic 
retinopathy contains an abnormally high concentration of prorenin and one wonders 
whether some of it may leak into the circulation and whether this may contribute to the 
abnormally high levels of prorenin in plasma. 
Our data show no uniform effect of panretinal photocoagulation on the plasma levels 
of prorenin. At any rule, there was no acute effect (one day). In some patients prorenin 
remained unchanged also after a longer follow-up period, others showed a decrease in 
prorenin but it should be noted that in most patients prorenin did not become normal. 
Although it is true that prorenin in vitreous fluid from eyes with proliferative diabetic 
retinopathy with retinal detachment is higher than in eyes with spontaneous retinal 
detachment, it is perhaps a priori unlikely that leakage of prorenin into the circulation 
leads to high plasma levels that are observed in diabetics. 
The ocular plasma flow is extremely low (24-26) as compared with total body plasma 
flow and the plasma half life of prorenin has been estimated to be in the order of 1-2 hours 
(27 ,28). This would mean that the veno-arterial prorenin gradient would be very high, 
more than 1000 mu~. if release of prorenin from the eye would be the cause of the 
abnormally high level in circulating plasma. 
If this were the case, one would expect to find very high levels of prorenin in some 
compartments of the eye. In fact, such high levels have not been measured. The highest 
levels of prorenin we measured in vitreous fluid in eyes with proliferative diabetic 
retinopathy were 172 mU/L (7). The highest levels of total renin (prorenin + renin) 
measured in tissues from bovine eyes were 15.3 ng Ang I per g tissue per hour in pigment 
epithelium-choroid as compared with 6.8 ng Ang I per g tissue per hour in plasma (29). 
In other words the high circulating plasma prorenin in patients with PDR cannot be 
fully explained by production from the affected eyes. 
However, this does not rule out any role for a local ocular RAS system in the development 
of diabetic retinopathy. Most of the elevated plasma prorenin is probably derived from 
production by renal orotherextrarenal sources or may be explained by a decreased renal 
or extrarenal clearance of prorenin or both. 
In conclusion, an elevated plasma pro renin is related to the presence of proliferative 
retinopathy partly independent of the presence of albuminuria and panretinal 
photocoagulation treatment may lead to decline of the elevated plasma prorenin level 
suggesting a relation between them. 
Based upon this data long-term clinical studies should be performed to examine whether 
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ACE inhibitor treatment has a favourable effect on the development and progression of 
retinal neovascularization in diabetic subjects. 
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ChapterS 
PLASMA PRORENIN AS AN EARLY MARKER OF MICROVASCULAR DISEASE 
IN PATIENTS WITH DIABETES MELLITUS 
Summary 
To test the hypothesis that a high plasma prorenin can be used as an early marker of 
microvascular complications in patients with diabetes mellitus plasma prorenin was 
measured in 44 patients with urinary albumin excretion between 30 and 300 mg/24h 
(microalbuminuria) and 120 patients with urinary albumin excretion below 30 mg/24 h 
(normoalbuminuria). A high plasma prorenin was associated with diabetic retinopathy, 
particulartythe proliferative type, serum creatinine andthe24h urinary albumin excretion 
rate. Plasma prorenin was not correlated with age, duration of diabetes, glyco-sylated 
hemoglobin, blood glucose, and blood pressure. The association between elevated 
plasma prorenin and retinopathy remained significant after adjustment for serum 
creatinine and albumin excretion. Independent of the presence or absence of micro-
albuminuria, the mean plasma level of prorenin was not above normal in patients without 
retinopathy and was 2 to 3times normal in patients with proliferative retinopathy. Thus 
retinopathy appears to be an important determinant of abnormally high plasma prorenin. 
Angiotensin converting enzyme (ACE) was elevated in the patients with diabetes 
mellitus as compared to control subjects but the plasma levels of ACE in diabetics with 
normoalbuminuria was not significantly different from the group with microalburinuria. 
Plasma prorenin was not associated with ACE. A plasma level of prorenin of 225 
mUlL had a sensitivity of 0.71 and a specificty of 0.71 for detecting.the presence of 
microalbuminuria. 
Introduction 
Human plasma contains two forms of renin : a) prorenin the enzymatically inactive 
precursor of renin and, b) renin the active enzyme (1 ,2). In plasma of normal subjects 
only 10 percent of the total renin concentration circulates in the form of renin and this 
percentage increases if the total renin concentration increases (2). The kidney is the 
major source of renin in plasma. The kidney is also an important source of plasma 
prorenin (3,4) but part olthe circulating pro renin originates from extrarenal sites such as 
the ovaries and testis (5.6) 
In patients with diabetes mellitus plasma prorenin is often high (7-10), whereas renin 
is normal or low (11, 12). There is a close association between a high level of plasma 
prorenin and diabetic complications (1 0). In diabetics without overt nephropathy plasma 
prorenin correlated positively with serum creatinine, the presence of macroalbuminuria 
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(Aibustix positive urine) and the presence of retinopathy. 
The association between elevated plasma prorenin levels and retinopathy remained 
significant after adjustment for nephropathy. 
Diabetic nephropathy will develop in about 40 percent of the patients with insulin 
dependent diabetes mellitus and is characterized by persistent macro-albuminuria, a 
decrease in glomerular filtration rate and an increase in blood pressure. This stage is 
preceeded by a stage of incipient nephropathy characterized by urinary albumin 
excretion below the detection limit of the Albustix but above the normal excretion of 30 
mg/day (microalbuminuria 30-300 mg/24h), and a normal or even high glomerular 
filtration rate. Microalbuminuria is regarded as a predictor of overt diabetic nephropathy 
(13). 
In the present study we examined whether plasma prorenin could be used as a marker 
of microvascular disease in a group of 120 diabetic patients with a normal urinary albumin 
excretion and 44 patients with incipient diabetic nephropathy. 
Subjects and methods 
Patients. 
Patients (n=164) attending our outpatient clinic were included in the study. Patients with 
a history of kidney, urinary tract, liver or heart disease were not included and also 
patients on drugs likely to affect the plasma level of renin were not included. All patients 
had serum creatinine of 120 llmoi!L or below. Some clinical characteristics of the 
patients are given in Table 1. In the study group 127 patients were on insulin, and 37 
patients were on oral antidiabetic drug treatment. An assessment of the 24 h urinary 
albumin excretion was made on three occasions in a period of one month. Microalbuminuria 
was defined as albumin excretion between 30-300 mg/24h, mean ofthree determinations 
(14). 
Ophthalmoscopy. 
Ophthalmoscopy after pupillary dilatation was done by the ophthalmologist who was 
unaware ofthe results of the renin measurements. Diabetic retinopathy was categorized 
as either background retinopathy or proliferative retinopathy. Background retinopathy 
was characterized by the presence of microaneurysms, whether or not combined with 
hemorrhages and hard exudates {15). Eyes with preproliferative retinopathy, as 
characterized by multiple cotton wool spots, venous abnormalities, beading and 
duplications, intraretinal microvascular abnormalities and diffuse large blot hemorrhages, 
were also categorized as background diabetic retinopathy. New vessels anywhere in 
the retina in either eye were categorized as proliferative retinopathy. Of the 45 patients 
with proliferative diabetic retinopathy 34 had been treated by laser photocoagulation of 
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one or both eyes 3-24 months before the study. 
Neurological assessment. 
Sensory or motor fibre neuropathy was defined as diminished sense of vibration at the 
lower or upper extremities and loss of Achilles and/or patellartendon reflexes (16). which 
generally is associated with other signs of neuropathy or with symptoms. such as 
sensory loss, distal paresthesia or pain. None of the patients had symptomatic 
orthostatic hypotension. 
Blood sampling. 
Blood samples for renin and prorenin were drawn from an antecubital vein after the 
patients had rested for 45 min in the supine position. Blood was also taken for serum 
creatinine, blood glucose, glycosylated hemoglobin (HbAc1) , angiotensin-converting 
enzyme (ACE) and noradrenaline. 
Measurements of plasma renin and pro renin. 
Measurements were made with an enzyme kinetic assay, in which the in vitro generated 
angiotensin I was quantitated by radioimmunoassay (17). For measuring prorenin, the 
proenzyme was converted to renin by trypsin (3,18). Normal levels of renin and prorenin 
in 255 normal subjects aged 18-62 yr were 14.3 (4.4-47.4) mUll (geometric mean and 
95% confidence interval) for renin and 140 (64-305) mUll for prorenin. 
Measurement of plasma noradrenalin and angiotensin converting enzyme 
Plasma noradrenalin was measured by high performance liquid chromatography (19) and 
angiotensin-converting enzyme (ACE) by an enzyme kinetic assay (20) . In normal 
subjects (n~57) aged 24-57 yr plasma noradrenalin was 1.5 (0.4) nmoi/L mean (SO) and 
ACE 14.9 ( 2.1 ) U/L. 
Urinary albumin. 
Albumin was measured by radioimmunoassay. The lower limit of detection was 
1 mgll and the interassay variability was 9 %. 
Statistical analysis. 
Differences between groups for discrete data were analyzed by CHI square test. 
Differences for continuous data were analyzed with the unpaired t-test or with the 
Student-Newman-Keuls test for multiple comparisons. Renin and prorenin were not 
normally distributed. Logarithmic transformation yielded apparently normal distributions 
with similar standard deviations in all groups. These transformed values were used for 
statistical analysis. Multiple regression analysis was performed wijh the use of the 
SPSS/PC+ program 1986 (SPSS Inc., Chicago, ILL, USA). 
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TABLE L ~ Clinical characteristics of diabetic patien.ts with and wi.thow microa!huminwia 
Absent Present P value 
n = 120 n = 44 
Sex (No. of female/male) 56/64 16/2S ru;• 
Ago (yc) 
Median 42 46 ns Range 17-76 20-76 
Duration of diabetes (yr) 
Median 13 16 ns Range !-44 20-76 
Insulin treatment 
(no. on insulin/ 
not on insulin) 
89/31 31/13 < 0.01 
Neuropathy 
(no of subjects; 88132 20/24 < 0.01 
absent/present) 
HbA1c [%; mean (SD)] 8.6 (L!) 8.8 (1.5) 
"' 
Serum creatinine (~mol/!) 
[mean; (SD)J 80 (16) 85 (21) ns 
Blood pressure (mmH~ 
Systolic [mean; SD)] 135123) 141 ~27) ns 
Diastolic [mean; (SD)] 77 11) so 13) ns 
Diabetic retinopathy (no.) 
Absent 63 12 
Background 31 13 < 0.01 
ProliJerative 26 19 
*p>0.05 Results 
Correlation of pro renin with diabetic complications 
In Tables 1 and 2 the patients are grouped according to the absence or presence of 
microalbuminuria. The groups did not differ significantly in sex, age, duration of diabetes, 
the use of insulin and blood pressure. Blood glucose, glycosylated hemoglobin, plasma 
angiotensin converting enzyme and noradrenalin were also not significantly different 
between the two groups. Patients with microalbuminuria had an increased prevalence 
of retinopathy and neuropathy in comparison to diabetics with normoalbuminuria. 
The plasma levels of prorenin in the patients without and with micro-albuminuria and with 
various degree of diabetic retinopathy are depicted in Figure 1 and Table2. The plasma 
level of prorenin in diabetics with normoalbuminuria was significantly higher (p<0.01) 
than plasma prorenin in age- and sex-matched healthy subjects. The highest plasma 
levels of prorenin were found in the the patients with proliferative retinopathy both in the 
normoalbuminuric group as well as in the group with microalbuminuria. Plasma renin was 
lower in diabetics with or without microalbuminura than in control subjects (P<O.OS). In 
72 patients plasma prorenin and 24 h urinary albumin excretion was measured atthree 
occasions. The coefficient of variation was 9 %(1-56), median and (range) for prorenin 
and 30%(1-135) for albuminuria. Thus there was much less variabilly (p<0.001) in 
plasma prorenin than in 24 h urinary albumin excretion. 
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TABlE II - Plasma renin. prorenin, noradrenalin and ACE in palienJS wilh and withouJ microalbu.mmuria 
Noradrenalin [pmoJJI,mean ;(SD)] 
ACE [U/l,mean ;(SD)] 
Renin [mU/1, geometric mean] 
range 
Prorenin [mUll, geometric mean] 
range 
*p>0.05 
Microalburninuria 
Absenr Presenr 
1.41 (0.58) 1.37 (0.53) 
15.6 (4.4) 17.6 (4.3) 
11.0 10.5 
2.5-48.4 2.2-39.0 
169 264 
52·548 71-990 
P value 
n' • 
ns 
n' 
< 0.01 
The influence of the various factors on the plasma level of prorenin was analyzed by 
multiple logistic regression analysis. The factors studied were: sex, age, duration of 
diabetes, insulin treatment, blood glucose, glycosylated hemoglobin, systolic and 
diastolic blood pressure, neuropathy, serum creatinine, angiotensin-converting enzyme, 
noradrenalin, 24h excretion of albumin and retinopathy. (Tabs 3,4). Statistical significant 
correlations were found with sex, creatinine, albumin excretion and retinopathy. Plasma 
prorenin was not correlated wijh angiotensin converting enzyme or plasma nor-
adrenaline. 
The multiple logistic regression analysis showed that high prorenin was positively 
associated with the presence of sex {male higher than in female, P<0.001), proliferative 
retinopathy (p<0.0001), albumin excretion rate (p<0.001) and negatively with diastolic 
blood pressure (p=0.002), and that the other factors including neuropathy and serum 
creatinine did not significantly contribute to the high plasma level of prorenin . It also 
appeared that the association with retinopathy was at least in part independent of the 
association with nephropathy. No significant correlations were found between the 
plasma level renin and the various factors mentioned above. 
A plasma level of prorenin of 225 mUll was derived from a Receiver Operating Curve 
as the best cut-off to detect the presence of microalbuminuria. The sensitively and 
specificity otthe plasma prorenine level for detecting microvascular disease in diabetics 
was 0.60 and 0.89 respectively. 
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TABLE Ill. - Correlation of (log) prorenin with various factors 
in patients with diabetes mellitus 
Factor r 
Age 0.113 
Duration of diabetes 0.237 
Systolic blood pressure - 0.099 
Diastolic blood pressure - 0.129 
Serum creatinine 0.323 
Blood glucose 0.090 
HbA1c 0.024 
ACE 0.085 
Noradrenaline 0.102 
24 h albumin excretion 0.316 
* p > 0.05 
P value 
ns * 
< 0.001 
ns 
ns 
< 0.001 
ns 
ns 
ns 
ns 
< 0.001 
TABLE IV. - Plasma levels of prorenin and renin in various categories of diabetics 
Renin Pro renin 
Factor Category n 
mUll P value mUll P value 
Sex Female 72 9.7 ns 152 
2.2-42.7 44-530 
Male 92 11.7 ns 226 < 0.01 
3.3-42.7 69-748 
Insulin On insulin 127 10.6 ns 200 
2.9-39.0 57-703 
Not on insulin 37 12.0 ns 162 < 0.01 
2.2-64.4 44-587 
Neuropathy Absent 108 11.0 ns 160 
2.6-46.0 53-482 
Present 56 10.1 ns 224 < 0.01 
2.5-40.0 65-774 
Retinopathy Absent 75 11.1 145 
2.3-53.7 53-393 
Background 44 10.2 ns 192 < 0.01 
2.7-38.2 51-723 
Proliferative 45 12.2 297 < 0.001 
3.4-43.7 93-946 
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Rg.1. 
CONTROLS 
Renin 0 NODR 
mU!ko: !.ill BGDR 
g POR 
20 
Prorenin 
mU/1 
500 
'" 
300 
200 
100 
CONTROLS 
0 NODR 
0 BGOR 
BPDR 
DIABETIC PATIENTS 
albuminuria 
< 30mg/21lh 
albuminuria 
30-300mg/2~h 
DIABETIC PATIENTS 
albuminuria 
< 30mg/2Uh 
... 
"' 
albuminuria 
30-3DOmg /211h 
... 
"' 
Plasma renin (upper panel) and prorenin (lower panel) in diabeticpatientsw~h normoalbuminuria 
or microalbuminuria. Patients were subdivided inthosewihout retinopathy (NOOR), with back-
ground retinopathy (BGDR) and thosewtth proliferative retinopathy (PDR). The numbers in 
the bar are the numbers of patients in each group. " p < 0.05 from healthy control subjects 
Results are expressed as the geometric mean xI : SO 
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Discussion 
Luetcher et al were the first to report a close association between a high level of plasma 
prorenin and the presence of microvascular complications in patients with longstanding 
diabetes mellitus (8). Other investigators, including our group, could confirm these 
findings (9,1 0). We found that the elevated plasma level of prorenin was associated with 
serum creatinine, the presence of macroalbuminuria and the presence of diabetic 
retinopathy, particularly the proliferative type. A number of confounding factors, i.e. sex, 
duration of diabetes, blood pressure, blood levels of glucose and HbAc1 , the prevalence 
of neuropathy or insuline treatment did not significantly contribute to this association. 
The association between plasma prorenin and retinopathy remained significant after 
adjustment for serum creatinine and the urinary albumin excretion rate .The present 
study, in a well-defined group of diabetics with incipient nephropathy confirms and 
extends the earlier observations made in patients with more advanced diabetic 
complications. 
Our results indicate that plasma prorenin level might be used as a marker for the 
presence of microvascular disease in patients with diabetes mellitus. Plasma prorenin 
level was already elevated in some patients with background retinopathy and a normal 
urinary excretion rate of albumin. Determination of plasma prorenin offers some 
advantages over measurements of urinary albumin excretion, because urine collection 
is not required and because of the lower day-to-day variability of plasma pro renin level. 
Prospective studies are necessary to see whether a high plasma prorenin level precede 
the development of microalbuminuria and/or retinopathy. In a retrospective study by 
Wilson et al it appeared that an increased plasma prorenin identified a group of young 
patients with diabetes who were at high risk for developing retinopathy and nephropathy 
(21). 
Serum levels of angiotensin-converting enzyme (ACE). a marker of endothelial cell 
function, were reported to be elevated in about 25 % of patients with diabetes mellitus 
(22,23). We also found that ACE was elevated in our subjects with diabetes in 
comparison with normal nondiabetic subjects. There was however no significant 
difference in the plasma levels of ACE in the patients with microalbuminuria in 
comparision with those with normal albumin excretion. 
The pathophysiology underlying the elevated plasma level of prorenin levels in 
patients with diabetes mellitus is not understood. There are two possibilities; a) an 
increase in the renal or extrarenal synthesis of prorenin or b) a reduced clearance. 
Rats with chronic streptozocin-induced diabetes mellitus show a significant fall in 
plasma renin accompanied by an increase in plasma prorenin (24). After bilateral 
nephrectomy plasma renin and prorenin decrease in control rats as well as in diabetic 
rats suggesting a renal origin for the high plasma prorenin levels. However, we did not 
found an elevated renal vein-to-artery ratio for plasma prorenin in diabetic patients with 
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end-stage renal disease and proliferative retinopathy, despite an elevated plasma level 
of prorenin and an impaired renal plasma fiow (9). 
An increase in the extrarenal production of prorenin may also explain high plasma 
prorenin levels. In human vitreous orsubretinal fluid the levels of prorenin are, expressed 
per mg albumin, in ccntrastto other plasma proteins, up to 100 times higher in the eye 
fluids than in plasma (25). Prorenin is higher in vitrous fluid from eyes with proliferative 
diabetic retinopathy ccmplicated by traction retinal detachment than in eyes of 
nondiabetics with spontaneous retinal detachment. In the bovine ocular tissue the 
highest ccncentration of pro renin was found in the pigment epithelium-choroid layer and 
in the retina (26). 
Misbin et al suggested that the high plasma level of prorenin is caused by autonomic 
dysfunction (27). Loss of adrenergic stimulation of the juxtaglomerular cells may lead 
to a decreased secretion of renin by the juxtaglomerular cells and then leads to a 
ccmpensatory increase in the synthesis and release from prorenin by these cells in 
diabetic patients with autonomic insuffiency. None of our patients had overt autonomic 
neuropathy and we found no association between plasma noradrenaline and prorenin. 
Moreover, patients with autonomic neuropathy in the absence of diabetes mellitus and 
its complications do not have high plasma prorenin levels (9). 
In summary, the high plasma prorenin in patients with diabetes mellitus is related to 
the development of microvascular disease and may be at least in part due to an increase 
production from extrarenal sources such as the eye, decreased clearance of prorenin 
from the circulation, or both. Plasma prorenin may be used as an early marker of diabetic 
microvascular disease but prospective studies are needed to prove that plasma prorenin 
measurements are useful to identify patients at risk for developing diabetic microvascular 
disease. 
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ChapterS 
BLOOD PRESSURE AND PRORENIN IN RELATION TO THE PROGRESSION OF 
ALBUMINURIA IN TYPE 1 DIABETIC PATIENTS WITH SUGHTLY ELEVATED 
URINARY ALBUMIN EXCRETION. A 2 YEAR FOLLOW-UP. 
Summary 
Microalbuminuria is a strong predictor of clinical nephropathy in Type 1 (insulin 
dependent) diabetes mellitus. Patients with microalbuminuria are also prone to the 
development of generalized microangiopathy . 
Plasma prorenin is often elevated in Type 1 diabetic patients, particularly when 
diabetes is complicated by retinopathy and albuminuria. An elevated plasma prorenin 
may therefore be a marker of microvascular complications. However, little is known 
about the elevation of prorenin overtime, in relation to development of microalbuminuria, 
during the course of diabetes. 
We conducted a two year prospective study in a selected group of normotensive 
Type 1 diabetic patients with slightly elevated levels of albuminuria. Progression of 
albuminuria was independently related to baseline blood pressure (p<0.001) and retino-
pathy (p<0.01) but not to baseline glomerular filtration rate (GFR) and metabolic control. 
Baseline prorenin-was elevated in only 6 of the 25 patients and was not different in 
patients with and without progression of albuminuria. 
Plasma prorenin was significantly higher in patients with exsudative or proliferative 
retinopathy. Thus, a relation between plasma prorenin and progression of albuminuria 
was not apparent in this group of patients. This may be explained by the low degree of 
albuminuria; prorenin may rise at later stages of renal diabetic disease. Another 
possiblity is that an elevated plasma prorenin is associated with a certain other aspect 
of microangiopathy of which albuminuria is not a representative sign. 
Introduction 
Microalbuminuria is considered to be a sign of diabetic microangiopathy and is used to 
distinguish Type 1 (insulin-dependent) diabetic patients who are at risk for future 
development of diabetic nephropathy from those who are not (1-4). Microalbuminuria 
shows a high degree of intrapatient variability so that repeated measurements are 
necessary to establish the presence and worsening of microalbuminuria (5-7). 
The plasma level of prorenin is often raised in Type t·(insulin-dependent) diabetic 
patients and high levels are related to the presence of proteinuria and severe retinopathy 
(8,9). It has therefore been suggested that prorenin can be used as an other marker of 
diabetic microangiopathy. 
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The much lower day to day variability of plasma prorenin as compared to urinary albumin 
excretion (1 0) may offer advantages in identitying patients at risk of progressive 
microangiopathy. 
It is important to determine at which time during the development of diabetic nephro-
pathy prorenin begins to rise and to detect factors that may contribute to the progression 
of albuminuria early in the course of diabetic renal involvement. Mosetti et al (11) have 
observed increased plasma prorenin when the rate of albumin excretion exceeded 40 
mg per day. Data reported by Wilson et al (12) suggest that in adolescent diabetics a rise 
in plasma prorenin may precede the development of renal and retinal disease. These 
authors, however, usedthepresence otmacroalbuminuria as a sign of renal involvement. 
In the present study we examined some clinical factors contributing to progression 
of albuminuria during two years follow-up in normotensive 
Type 1 (insulin-dependent) diabetic patients selected to have minor elevations in urinary 
albumin excretion. Plasma prorenin was measured serially to investigate whether its 
level can be used as a marker of progressive albuminuria. 
Patients and methods 
Patients and follow up. 
The study was approved by the local medical ethics committee and all participating 
patients gave informed consent. Patients with Type I (insulin-dependent) diabetes 
mellitus and elevated urinary albumin excretion rate were selected from an out-patient 
population. Glucagon-stimulated C-peptide levels were less than 0.2 nmol/1. 
Diabetes had to be present for at least five years and all patients self-monitored their 
blood glucose levels. Patients with a mean overnight urinary albumin excretion rate 
between 10 and 200 ug/min determined in three consecutive collections were included 
in this study. In overnight urine collections a cut-off level of 10 g/min represents the upper 
normal limit (above the 97.5 th percentile for non-diabetic patients) in our clinic. It should 
be noted that this inclusion criterium is lower than the internationally proposed level of 
20 ug/min to define microalbuminuria. 
The exclusion criteria were: urinarytract infection or renal tract abnormalities, hypertension 
( > 160/95 mmHg) and the use of antihypertensive medication. A total of 25 consecutive 
patients were selected forth is study. Their sodium intake was unrestricted an none used 
a low protein diet. The prospective follow-up was started within three months after 
selection ofthe patients. All participants completed the study. The patients were studied 
at 4 month intervals. On each occasion three overnight urine specimens were obtained 
for determination of albumin excretion and one 24-h urine collection was obtained for the 
determination of sodium and urea excretion. 
Blood pressure was measured according to the method of Riva Rocci Phase V of 
Korotkoff after the patients had been sitting for five minutes, and the results of three 
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measurements were averaged. Glomerular filtration rate (GFR) and effective renal 
plasma flow (ERPF) were determined at the beginning of the study, after one and two 
years. 
Blood was drawn, from an anticubal vein after the patients had rested for 10 minutes 
in the sitting position, to measure renin, total renin (renin plus prorenin) and HbA 1. Blood 
samples were centrifuged at room temperature for 1 0 minutes and the plasma was stored 
at -20 oc. 
Analytical procedures 
The plasma levels of renin and total renin (renin and prorenin) were measured according 
to previously described methods (13,14). Prorenin was calculated as the value for total 
renin minusthevalueforrenin. We here reportthevaluesfortotal renin as well forprorenin 
and renin seperately because the samples were analysed two years after blood 
collection. During storage at -20 oc some prorenin to renin conversion takes place, 
resulting in renin levels that are higher and prorenin levels that are lower than in vivo. The 
sum of the two, total renin, does not change. 
Normal levels (geometric mean and 95% confidence interval) of renin, prorenin and total 
renin in 255 normal subjects aged 18-62 were 14.3 (4.4-47.4) mU~. 140 (964-305) mU/ 
L and 160 (65-300) mU/L respectively. 
Plasma prorenin levels above 225 mU~ were considered to be abnormal (10). 
Urinary albumin was measured by a commercially available double-antibody radio-
immunoassay (Diagnostic Products Corporation, Apeldoorn, The Netherlands). 
Hemoglobin A1 was measured by colorimetry (15), reference values: 4.5 to 5.8%. 
G FR and ERPF were measured simultaneously as the clearance of 1251- thai am ate and 
131 1- hippuran, respectively (16,17). To prevent ketosis and hyperglycaemia during the 
renal haemodynamic studies the patients received an intravenous glucose solution and 
regular acting insulin. Blood glucose was monitored every half hour and kept between 
4.4 and 8.4 mmol~ by adjusting glucose infusion. After4 hours to normalize and stabilize 
blood glucoses, GFR and ERPF were determined over a 2-hour period. 
Retinopathy was assesed by fundoscopy through dilated pupils and classified by an 
opthaJmologist for the worse eye as: absent, microaneurysms. exsudative retinopathy, 
and proliferative retinopathy. 
Statistical analysis 
Data are expressed as mean± SO or as mean± SEM (figures) except urinary albumin 
excretion values and renin data which are given as the geometric mean and 95% 
confidence intervals. Changes in variables were analyzed by two-way analysis of 
variance according to Friedman. In addition, paired and unpaired Wilcoxon tests and 
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Kruskhal Wallis analysis of variance were used when appropriate. Adjustment for 
multiple comparisons was carried out using Duncan's method. Differences in proportions 
of variables among subgroups were assessed by chi-quare statistics or Fisher exact 
test. The independent contribution of parameters to progression of albuminuria and to 
plasma renin and prorenin was evaluated by multiple regression analysis. A two-sided 
p-value < 0.05 was considered to be significant 
Results 
Progression of albuminuria was assessed by comparing the pooled urinary albumin 
measurements obtained during the second year of follow-up with the baseline 
measurements. An increase of 25% or more from baseline was defined as progression. 
According to this criterion, 13 patients showed progression of albuminuria. 
The clinical characteristics of patients with progression (n=13) and those without 
progression (n=12) of albuminuria are presented in Table 1. 
There were no differences with respect to age, sex distribution, diabetes duration, 
insulin-dose, metabolic control between the two groups. 
Body mass index was higher (p<0.02) and retinopathy was more severe (p<0.05) in the 
progressors as compared to the non-progressors. 
At the start of the study urinary albumin excretion was not different between the 
progressors and non-progressors (P>0.60). A significant difference in urine albumin 
excretion was seen from 16 months on ward (Fig. 1). 
Systolic blood pressure was significantly higher in the progressors at the start and 
during the course of the follow-up period (Fig. 2). Diastolic blood pressure was not 
significantly different (p<0.07) at baseline but was higher during the follow-up period of 
the study in the progressors. 
At the start both GFR and ERPFwere not different between the groups. (Table 2). GFR 
was significantly decreased after two years in both groups. The decrease in ERPF after 
two year follow-up was not significant in either group. 
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Table 1. Baseline characteristics of patients according to progression of albuminuria. 
Age yr 
Sex male/female 
Duration of diabetes yr 
Body mass index kg/m' 
lnsuline dose Ulkg/day 
HbA\ % 
Systolic blood mmHg 
pressure 
Diastolic blood mmHg 
pressure 
Retinopathy a/m'e+p' 
Albuminuria ~g/min 
No progression 
of 
albuminuria 
40 (21-59) 
1012 
20 (5-45) 
23.0±1 .4 
0.70±0.18 
7.3±1.5 
120±2 
72±2 
412/6 
32 (14-72) 
Progression 
of 
albuminuria 
4S (23-58) 
1112 
21 (10-44) 
24.8±2.5 
0.79±0.29 
7.8±1.4 
135±4· 
77±2• 
017/6"" 
25 (14-25) 
Results are expressed as mean± SO, when data are normally distributed and as geometric mean and 
95% confidence interval when data are not normally distributed. 
"p <0.05from patients without progression of albuminuria. (unpairedt-testiorblood pressure, and Fisher 
exact test for presence or absence of retinopathy. 
')a;::: retinopathy absent, m;::: microaneurysm, e=: exsudative retinopathy, 
p;::: proliferative retinopathy. 
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Albuminuria 80 
JJ9 /min 
60 
40 
20 
-4 
e non-progressors 
0 progressors 
0 4 8 12 16 20 24 months 
Fig.1 Albuminuria duringtwoyearsfollowup. Resuttsare presented as geometric mean ±sem (antilog 
of mean after logarnhmictransfomation). Progessors. open circles (n=13) and nonprogressors 
closed, circles (n=12). 
Table 2. Renal hemodynamics. Comparison between patients with and without progression ofalbuminuria. 
Renal hemodynamic 
parameter 
Glomerularfittration 
rate (mVmin/1.73 m') 
Effective renal plasma 
flow (mVmin/1.73 m') 
progression 
of albuminuria 
no 
yes 
no 
yes 
start of 
study 
127±7 
123±8 
535->-...29 
510±44 
1 year 
follow-up 
122±6 
120±5 
520-...28 
502±38 
2 years 
follow-up 
115±7" 
115±5"" 
501±29 
482±37 
Data are mean± SEM. ,. .. p<0.01 paired t-test with adjustment for multiple comparison for difference from 
value at the start ofthe study. 
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Atthe start both GFR and ERPF were not different between the groups. (Table 2). GFR 
was significantly decreased after two years in both groups. The decrease in ERPF after 
two year follow-up was not significant in either group. 
Blood pressure 
mmHg 150 
e non-prog ressors 
o progressors 
systolic 
diastolic 
:! :1 :1 ! :r -1. 
so~-~--~--~---L--~--~~ 
-4 0 4 8 12 16 20 24 months 
Fig2 Systolic and diastolic blood pressureduringtwo years follow up. Results are presented as mean 
± sem. Progessors, open circles (n=13) and non-progressors, closed circles (n=12). 
Metabolic control, as judged by HbA 1 measurement, was comparable in the two groups 
during the study: HbA 1, at baseline, during the first year of follow-up and during the 
second year offollow-up, was 7.9 ± 1.4%, 8.2 ± 1.1% and 8.0 ± 0.4% respectively in 
the progressors and 7.3 ± 1.5%, 8.5 ± 0.4% and 8.1 ± 0.4%, respectively, in the non-
progressors. 
The 24 hour urinary excretion rates of sodium and urea were not different in the two 
groups at the start and did not change significantly during the study. The mean urinary 
sodium excretion was 154 ±48 and 170 ±44 mmol/24h in the progressors and the non-
progressors and the mean urea excretion was 371 ± 77 and 390 ± 82 mmol/24h, 
respectively. 
Total renin (renin plus prorenin) and prorenin were not significantly different between 
the two groups at the start of the study (p>0.40). 
Baseline plasma prorenin was abnonmally elevated (above 225 mum in only 6 out of the 
25 patients. Total renin did not significantly change during the follow-up period (Table 3, 
Figure 3). 
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Table 3. Plasma levels of total renin in patients with and without progression of albuminuria. 
Progression 
of albuminuria 
no 
yes 
start of 
study 
total renin (ml Ill ) 
251 (184-343) 
205 (159-265) 
2 year 
follow-up 
240(187-341) 
165 (140-227) 
Data are expressed as geometric mean and 95% confidence interval. 
Total n:nrn 
mUA. 
'" 16 ~0 24 
mor"tns 
bO~ 1 
• nor,-o,ogre!'~oc•. 
<:> oroo,<":>~or·. 
12 , 6 20 ?~ 
•TIOr>1t"l,. 
! lO+ 
i 
I 
100~ 
1: 1~ 20 ;;_, 
m<:mtn~ 
Fig.3 Plasmal eve! oftotal renin, prorenin and renin duringtwoyearsfollowup. Resuttsarepresented 
as geometric mean ±sem (antilog of mean afterlogarithmictransfomation). Progessors, open 
circles (n=13) and non-progressors, closed circles (n=12). 
Renin decreased significantly during follow-up (Fig. 3). 
This finding can be explained by the time-related cryoactivation by which prorenin is 
converted to renin during handling of plasma at lowtemparature and storage at -20'C (see 
Methods). As is shown in Table 4, total renin were higher in patients with exsudative 
retinopahty or proliferative retinopathy. 
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Table 4. Plasma levels of total renin in patients with and without retinopathy at start of study aftertwoyear 
follow-up. 
Type of retinopathy Total renin {rot W) 
no 
microaneurysm 
exsudates and/or 
proliferation 
start of 2 years 
study follow-up 
150 (81-232) 145 (97-232) 
225 (156-316)' 215 (147-316)' 
249 (177-355)' 230 (166-130)' 
Data are expressed geometric mean and 95% confidence interval. * p < 0.05 with adjustment 
for multiple comparison after logarithmic transformation of the data, for difference with 
patients without retinopathy. 
Progression of albuminuria (as the two years relative change in albuminuria after 
logaritmic transformation) was independently associated with baseline mean arterial 
blood pressure (p=0.001) and with the presence of retinopathy (p=0.001) but not with 
baseline GFR (p=0.17), baseline plasma prorenin (p=0.21) and baseline HbA 1 (P=0.32). 
The levels of urinary albumin excretion during the second year of follow-up was 
independently related to the baseline albuminuria (p<0.001), baseline mean arterial 
pressure (P= 0.001), but again not to baseline GFR (p= 0.17) and baseline plasma 
prorenin (P= 0.19). Urinary albumin excretion during follow-up was also correlated with 
the degree of retinoapthy at the start of the study (P= 0.01). The prorenin levels at the 
start of the study and during folow-up were independently related to the presence of 
retinopathy (p= O.Q1 and 0.007), to the duration of diabetes (P= 0.03 and 0.03) and to 
the body mass index (P= 0.05 and 0.02). Pro renin was not related to GFR, mean arterial 
pressure and albuminuria either at the start of this study or during follow-up (p>O.S for 
all parameters). 
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Discussion 
An important finding of this study was the lack of an association between the levels of 
prorenin and the progression of albuminuria. Progression of albuminuria was not related 
to baseline total renin and pro renin levels. Furthermore, plasma total renin and prorenin 
did not significantly change during the two years of follow-up. The present findings 
therefore do not support the hypothesis that patients with an early rise in albuminuria can 
be identified by plasma prorenin measurement. 
It is possible that an elevated plasma prorenin is associated only with higher levels 
of microalbuminuria or even with macroalbuminuria. 
Indeed, although it has been reported that a rise in plasma prorenin can precede the 
development of microvascular complications (12), the presence of macroalbuminuria 
was used as a sign of the presence of diabetic renal disease. Patients with either 
intermittent or continious microalbuminuria tended to have higher levels of plasma 
prorenin than patients without microalbuminuria, but the difference was not statistically 
significant. Only macroalbuminuria was significantly correlated with plasma prorenin 
(12). The lack of a correlation between elevated plasma prorenin and early abnormalities 
in albuminuria in our study is in agreement with recent prospective data in non-
hypertensive Type 2 (non-insulin dependent) diabetic patients (18). 
In our study the level of plasma prorenin was significantly related to the presence of 
rather advanced retinopathy which is in accordance with previous cross-sectional (8, 1 0) 
and prospective studies (11), suggesting retinopathy to be more important factor related 
to plasma prorenin than microalbuminuria. 
Another explanation of our results might be that elevated plasma prorenin is 
associated with a certain aspect of diabetc microangiopathy of which albuminuria is not 
a representative sign. 
The mechanisms responsible for the association between high pro renin levels and 
diabetic complications are not known. Reduced renal clearance of prorenin due to 
alterations in the processing of prorenin to renin in the juxtaglomerular cells could be a 
mechanism. Reduced extra-renal clearance of prorenin due to impaired endothelial 
function or glycosylation of prorenin with impaired intemalisation of plasma-derived 
prorenin as a result is another possibility (8,9,19,20). Finally, increased extra-renal 
production of prorenin through activation of local renin-angiotensin systems, for instance 
a local renin-angiotensin system in the eye, might also contribute to the high level of 
plasma prorenin in patients with diabetic retinopathy (21-23). 
Another important finding of this study was the presence of a correlation between 
blood pressure and progression of albuminuria. Both systolic and diastolic blood 
pressure were significantly higher, albeit still in the normal range, in the second year in 
subjects with progression of albuminuria (Figure 1). These findings support the concept 
that a rise of blood pressure is associated with progression of renal involvement even 
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at a very early phase (24). This would strenghten the argument to lower blood pressure 
in microalbuminuric patients without hypertension (25-27). Progresssion of albuminuria 
was not significantly related to baseline GFR. In both groups (progressors and non-
progressors) 4 patients had glomerular hyperfiltra!iOn at the start of the study. During 
follow-up GFR decreased independently of progression of albuminuria. Other studies 
have shown that glomerular hyperfiltration as such can contribute to the development 
of diabetic nephropathy (28,29) but this has not been consistently reported (30,31). 
Improved metabolic control has been shOwn to delay the progression of albuminuria 
(32). In our study glycosylated haemoglobin was not different at the start and did not 
change during follow-up in both between progressors and non-progressors of albuminuria. 
This can probably explained by the fact that all patients were accustomed to self 
monitoring their blood glucose levels and thereby narrowing the range of metabolic 
control. Progression of albuminuria was also independently associated with the pre-
sence and severity of retinopathy suggesting a relation between the micro-angiopathy 
at the renal and retinal level. 
In conclusion, prorenin measurement does not appearto adequately predict progression 
of albuminuria in Type 1 diabetic patients with slightly elevated urinary albumin 
excretion. Progression of albuminuria is correlated with blood pressure, even when blood 
pressure is in the normal range and renal involvement is at an very early stage. 
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Chapter7 
SUMMARY 
7. 1 Background and aim of research 
The renin-angiotensin system (RAS) plays an important role in the regulation of arterial 
blood pressure and water and salt regulation. 
Until recently this system was considered to be exclusively a circulating endocrine 
system. Circulating renin, released by the renal juxtaglomerular cells, reacts with 
hepatically derived angiotensinogen (renin substrate) to form the inactive decapeptide 
angiotensin I (Ang 1). Ang I, in turn, is converted to the biologically active octapeptide 
angiotensin II (Ang II) by angiotensin converting enzyme (ACE) which is bound to the 
endothelial cell membrane. Ang II formed in the circulation diffuses to the tissues where 
it stimulates specific receptors on the surface of vascular smooth muscle cells as well 
as on the surface of the aldosterone-producing cells in the adrenal glands. 
More recent evidence, however, suggests that, in addition to the circulating 
endocrine RAS, there exist local or tissue renin-angiotensin systems in which Ang I and 
Ang II are formed in the tissues ratherthan in the circulation. Tissue production of these 
peptides may be catalyzed either by locally synthesized renin and renin substrate or by 
renin and renin substrate that are taken up from the plasma. Local renin-angiotensin 
systems have both autocrine and paracrinefunctions. Messenger RNA (mRNA) for renin 
has been demonstrated not only in the kidney but also in such organs as the adrenals, 
ovaries, testes, and brain, and mRNA for angiotensinogen has been found in all of these 
tissues as well. On the other hand, renin in the heart and blood vessel wall probably 
originates mainly in the kidneys and is then taken up from the circulation. 
Human plasma contains not only renin but also its enzymatically inactive precursor 
prorenin. Virtually all plasma renin is derived from the kidney, as evidenced by the 
observation that circulating renin levels are extremely low or not demonstrable in 
anephric patients. The kidney is also an important source of circulating prorenin. 
However the finding that anephric patients have plasma prorenin levels that are 30-40% 
of normal indicates that a proportion of circulating prorenin is clearly of extrarenal origin. 
It is likely that such organs as the adrenals, testes, and ovaries release not renin but 
prorenin into the circulation. For example, the increased plasma prorenin levels seen in 
pregnant women are largely derived from the ovaries. 
Unlike plama renin, plasma prorenin is increased in patients with diabetes mellitus 
who have microvascular complications. The mechanisms that account for the elevations 
in plasma prorenin levels seen in these patients are yet unknown. In patients receiving 
a beta-adrenoreceptor antagonist (beta-blocker), plasma renin levels fall and plasma 
prorenin levels rise. 
Thus, it has been proposed that the development of autonomic neuropathy in patients 
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with diabetes mellitus may be responsible for the increase in plasma pro renin. Loss of 
sympathetic stimulation ofthe beta-adrenoreceptors on the juxtaglomerular cells might 
result in diminished secretion of renin and, as a compensatory mechanism, the 
synthesis and secretion of prorenin in the juxtaglomerular apparatus might be augmented 
According to an alternative hypothesis, when the juxtaglomerular cells are affected 
by diabetic micrangiopathy, conversion of prorenin to renin in these cells decreases and 
secretion of prorenin consequently increases. 
A third explanation for the elevated plasma prorenin levels may be increased production 
and secretion from an extrarenal source such as, for example, blood vessel walls 
damaged by diabetic micrangiopathy. It is also possible that the rise in plasma prorenin 
may be attributable not so much to increased production as to abnormal elimination of 
this prohormone from the circulation. 
The first aim of our research was to address the question of whether an elevation in 
plasma prorenin is, in fact, an indicator of diabetic microangiopathy and, if so, with which 
type of complication (retinopathy, nephropathy, or neuropathy) is it associated?. 
The possibility that increased plasma prorenin may be linked to changes in carbohydrate 
metabolism was investigated by attempting to correlate hemoglobin A1c and blood 
glucose levels with prorenin levels in insulin-dependent as well as non-insulin-dependent 
patients. 
The selective hyperproreninemia in diabetic patients may stem from increased renal 
or extrarenal production of prorenin or from decreased dearance, or a combination ofthe 
two. We studied the first possibility by comparing the renal arteriovenous gradient of 
prorenin in diabetic patients who had high prorenin levels with that in non-diabetic 
subjects. 
Our group's previous research has shown the presence of a local RAS in the human 
eye. In addition, mRNAs for prorenin, angiotensinogen, and ACE have been demonstrated 
in the choroidal tissue. The clear correlation between elevated plasma prorenin levels 
and the presence of diabetic retinopathy pointed to the eye as a probable source of the 
increased prorenin. Accordingly, we studied the influence of panretinallasercoagulation 
on plasma prorenin levels in patients with proliferative diabetic retinopathy. 
7.2 Plasma prorenin in patients with or without diabetic microvascular complications. 
In a group of 223 patients with diabetes mellitus (Chapter 2) plasma prorenin levels 
correlated with the presence of nephropathy as well as with the presence of retinopathy, 
particularly the proliferative form. Retinopathy appeared to be a stronger determinant of 
prorenin concentration than did nephropathy, however. Plasma prorenin was already 
elevated in patients with proliferative retinopathy who still had urinary albumin 
concentrations in the normal range below 30 mg/24h.ln contrast, plasma prorenin levels 
remained normal in patients who had proteinuria greaterthan 300 mg/24h but did not have 
retinopathy. The highest prorenin concentrations were observed in patients with both 
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nephropathy and retinopathy. Multiple regression analysis showed no significant 
influence of age, duration of diabetes, gender, blood glucose concentration, HbA1c 
concentration, insulin use, or the presence of neuropathy on the correlation between 
prorenin and the presence of retinopathy or nephropathy. 
In seven patients with both serious nephropathy and retinopathy who underwent renal 
arteriography in preparation for eventual renal transplant, we found no significant 
difference between renal vein prorenin and renal artery prorenin levels, despite a marked 
elevation in peripheral plasma prorenin and a diminution in renal blood flow. It is thus 
unlikely that the increased plasma prorenin in patients with diabetes mellitus can be 
attributed solely to increased renal secretion. 
In contrast, we found no elevations in plasma prorenin levels in 16 patients with 
serious non-diabetic autonomic neuropathy. This appears to rule out autonomic diabetic 
neuropathy as an explanation for the elevated plasma prorenin levels found in patients 
with microvascular complications. 
7.3 Pro renin in the ocular fluid of patients with diabetic retinopathy 
Extrarenal renin-angiotensin systems are found predominantly in highly vascular 
organs. These extrarenal systems appear to release prorenin but not renin into the 
extracellular fluid. It is possible that the intracellular conversion of prorenin to renin may 
lead to the formation of Ang I and Ang II. The eye is a highly vascular organ and retinal 
neovascularization is an important aspect of diabetic retinopathy. Recent research has 
shown that Ang II can stimulate vessel wall growth. Application of Ang II to the comea 
of the rabbit eye stimulates corneal neovascularization. Moreover, Ang II receptors have 
been demonstrated in the retinal vessels. 
We investigated the presence of diverse components of the RAS in ocular fluid 
obtained from human eyes during surgery in diabetic as well as nondiabetic patients 
(Chapter 3). Prorenin was present in aqueous humor, vitreous fluid, and subretinal fluid 
and its concentration in vitreous and subretinal fluid was many times higher than would 
be expected on the basis of the serum protein content of these fluids. In particular, the 
vitreous fluid from patients with diabetic retinopathy contained twice as much prorenin 
(relative to serum albumin) as did that from nondiabetic patients, whereas vitreous 
angiotensinogen content (relative to serum albumin) did not differ between the two 
groups. It is noteworthy that the vitreous fluid contained virtually no renin. These 
observations are consistent with local production of prorenin in the eye. Taken together 
with the recent discovery of mRNA expression of renin, angiotensinogen, and ACE in 
human eye tissue, ourfindings argueforthe existence of an intraocular renin-angiotensin 
system and suggests a roleforthissystem in the development of retinal neovascularization 
in diabetes mellitus. 
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7.4 Effect of panretinal photocoagulation on plasma prorenin levels in patients with 
diabetic retinopathy 
Proliferative retinopathy is a major cause of blindness in patients with diabetes mellitus. 
There is evidence that retinal hypoxia sets the stage lor neovascularization and that the 
production of growth factors by the ischemic retina plays an important role in this 
process. The treatment of proliferative diabetic retinopathy consits of panretinal 
photocoagulation, which leads to the regression of neovascularization. Although the 
mechanism of action of laser treatment remains to be clarified, one hypothesis is that 
this theapy reduces the production of growth factors. 
We studied the effect of laser treatment on plasma prorenin levels in 12 patients with 
previously untreated proliferative retinopathy (Chapter 4). 
The rationale for these studies was that the finding of a decrease in elevated plasma 
prorenin levels following laser treatment would provide evidence that prorenin is 
produced by the diabetic eye from which it then enters the circulation. Although the mean 
prorenin value did indeed decrease four weeks after the last laser treatment the results 
were not unequivocal. Plasma prorenin levels fell in only half of the patients and, despite 
this decrease, remained higher than normal. Thus, definitive conclusions cannot be 
drawn regarding the effect of laser treatment on plasma prorenin levels. Possible causes 
of the ambiguity in our results include the small number of patients studied, the lack of 
an control group, and the use of concomitant medications that can influence plasma 
prorenin levels. 
It is not likely that leakage of prorenin from the eye contributes significantly to the 
elevated plasma prorenin levels found in patients with proliferative retinopathy. Low 
plasma flow in the eye (0.3 ml/min) and the relative long plasma half-life of prorenin 
(1-2h) would lead one to expect extremely high prorenin levels in one or more ocular fluid 
compartments. Such levels have not been found in the extracellular vitreous fluid of 
patients with diabetes. 
7.5 Plasma prorenin in diabetic patients with microalbuminuria 
There is currently no biochemical markerforthe development and progression of diabetic 
microangiopathy. The identification of such a marker would be an important contribution 
to the diagnosis and management of patients with diabetes. In chapter 5 we describe the 
relationship between prorenin and microvascular complications in 164 diabetic patients 
with or without microalbuminuria. These patients did not have macroalbuminuria and 
were thus either free of nephropathy. 
Plasma prorenin levels were correlated with the presence of retinopathy as well as 
microalbuminuria. The magnitude ofthe elevation in plasma prorenin level proved to be 
related to the seriousness of retinopathy or nephropathy, with the highest values found 
in patients who had both proliferative retinopathy and albuminuria. This cross-sectional 
study supports the possibility that an elevated plasma prorenin level may be an early 
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marker of progressive microangiopathy. Although microalbuminuria has been viewed by 
many investigators as an indicator of progressive microvascular nephropathy, it is a 
highly variable parameter, influenced by many factors including posture, exercise, diet, 
metabolic regulation, and arterial blood pressure. 
We measured plasma prorenin levels and albumin excretion in a group of 72 patients 
with insulin-dependent diabetes on three different occasions over a four-week period. 
The variation coefficient of prorenin was only 9 %, as compared with 35% for albumin 
excretion. Thus, proreni n measurements yielded far less variable results than did 
albuminuria determinations. Plasma prorenin measurements proved to have 72% 
specificity and 72% sensitivity as a diagnostic test for the presence of albuminuria in 
a group of 140 patients with insulin-dependent diabetes mellitus. The sensitivity and 
specificity of the test for the presence of retinopathy and/or albuminuria were 60% and 
89%, respectively. We therefore concluded that an elevated plasma prorenin level is not 
a sufficiently sensitive marker for the presence of microangiopathy. Nevertheless, it is 
possible that plasma prorenin measurements can be used to follow the course of 
microvascular complications in patients with diabetes mellitus. Longitudinal studies will 
be necessary to supplement the data from our cross-sectional studies. 
It is not yet known whether the elevation in plasma prorenin represents an early or 
late stage of microvascular complications. There is evidence that an increased plasma 
prorenin level may appear prior the first clinical manifestations of microvascular 
complications. We undertook a two-year prospective study of plasma prorenin 
concentrations and the progression of albuminuria in a group of25 normotensive patients 
with insulin-dependent diabetes mellitus who had slightly elevated albumin excretion 
(Chapter 6). We observed no relationship between the progression of albuminuria and 
plasma prorenin values and found no changes in plasma prorenin during the two-year 
follow-up period. Progression of albuminuria was related to blood pressure (although 
blood pressure was not elevated according to WHO criteria) and to the presence of 
retinopathy. Retinopathy appeared to be a stronger determinant than microalbuminuria 
of elevated plasma prorenin. 
These findings do not support the hypothesis that plasma prorenin measurements 
can be used as an early indicator of progression of albuminuria. It is possible that 
increase in plasma prorenin appearwith higher albumin excretion or that elevated plasma 
prorenin levels are associated with certain aspects of microangiopathythat are unrelated 
to the development of microalbuminuria. 
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7. 6 Therapeutic implications 
Drugs that influence the RAS system, such as ACE inhibitors, have been shown to 
reduce albuminuria in patients with type 1 diabetes mellitus and nephropathy, even in 
those who are normotensive (1-4). There is evidence that treatment with ACE inhibitors 
slows the progression of diabetic nephropathy, through an action that is partially 
independent of the blood pressure lowering effects of these agents (5-7). 
Our research provides clear evidence for the existence of an intraocular renin-
angiotensin system and suggests a role for this system in the development of diabetic 
retinopathy. It is possible that elevated plasma prorenin levels may reflect stimulation 
of a local renin-angiotensin system in tissues with microvascular abnormalities. 
Drugs that affect the RAS, such as ACE inhibitors, specific renin inhibitors, and Ang 
II antagonists may have therapeutic potential in patients with diabetic retinopathy. 
Parving et al (8) recently demonstrated that an ACE inhibitor decreased protein leakage 
from the retinal vessels in eyes with background retinopathy. Studies of the effect of 
ACE inhibitors on the development and progression of retinal neovascularization in 
patients with diabetes mellitus are certainly warranted. 
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ChapterS 
SAMENVATTING 
8.1 Achtergrond en doe/ van het onderzoek 
He! renine-angiotensine systeem (RAS) speelt een belangrijke rol bij de regulatie van de 
arteriele bloeddruk en de water- en zouthuishouding. 
Tot voor kort werd dit systeem uitsluitend als een in het plasma circulerend endocrien 
systeem beschouwd. Circulerend renine, afgescheiden door de juxtaglomerulaire cell en 
in de nieren. reageert met angiotensinogeen afkomstig uit de lever, waarbij he! inactieve 
prohormoon angiotensine I (Ang I) word! gevormd. Ang I word!, door he! aan de 
membraan van endotheelcellen gebonden angiotensine converterend enzym (ACE), 
omgezet in het biologisch actieve angiotensine II (Ang II). Het in de circulatie gevonmde 
Ang II diffundeert naar de weefsels en stimuleert specifieke receptoren op het 
celoppervlak van gladde spiercellen in de vaatwand en op het oppervlak van de 
aldosteron producerende cell en in de bijnierschors. 
Behalve dit circulerende endocriene renine-angiotensine systeem zijn er inmiddels 
aanwijzingen voor het bestaan van lokale of weefsel renine-angiotensine systemen. 
Lokaal wil zeggen dat Ang I en II niel in de circulatie worden gevormd maar in de 
weefsels. Dit kan door lokaal gesynthetiseerd renine en renine substraat (angioten-
sinogeen) of door renine en renine substraat afkomstig uit het plasma. Lokale renine-
angiotensine systemen hebben autocriene and paracriene functies. 
mRNA's van renineen angiotensinogeen zijn o.a. aangetoond in denier, bijnier, ovarium, 
testis en hersenen. Renine in het hart en de vaatwand is waarschijnlijk grotendeels 
afkomstig uit de circulatie en is geproduceerd door de nier. 
Menselijk plasma bevat naast renine ook prorenine, de enzymatisch inactieve 
voorloper van renine. Vrijwel al he! renine in he! plasma is afkomstig van de nier; bij 
nierloze patienten is het circulerende renine zeer laag of niet aantoonbaar. De nieris ook 
een belangrijke bron van het circulerende prorenine, echtereen dee I van hetcirculerende 
prorenine heel! een extra-renale oorsprong; bij nierloze patienten is het prorenine in 
plasma 30-40 % van normaal. Organen, zoals bijnier, testis en ovarium, geven 
waarschijnlijk prorenine aan he! circulerende bloed af en geen renine. Het verhoogde 
plasma prorenine bij zwangere vrouwen bijvoorbeeld is voor een groat gedeelte af-
komstig uit het ovari um. 
Plasma prorenine is, in tegenstelling tot plasma renine, verhoogd bij patienten met 
diabetes mellitus met microvasculaire complicaties. 
Welk mechanisme aan dit verhoogde plasma prorenine ten grondslag ligt, is nog 
onbekend. Bij patienten die met een beta-adrenoceptor antagonist (beta-blokker) 
worden behandeld daalt he! plasma renine en stijgt he! plasma prorenine. Er is daarom 
geopperd dat het optreden van auto nome neuropathie bij diabetes mellitus verantwoordelijk 
106 
zou zijn voor het verhoogde circulerende plasma prorenine. Verlies van sympathische 
stimulatie van de beta-adrenoceptoren op de juxtaglomerulaire cell en in denier zou een 
verminderde secretie van renine geven. Hierdoor zou compensaloir een toe name van de 
synthese en secretie van prorenine in he! juxtaglomerulaire apparaat optreden. 
Een andere hypothese gaat uit van een verminderde omzening van proreninetot reni-
ne in de juxtaglomerulaire cell en en dientengevolge een verhoogde secretie van prore-
nine, wanneer deze cell en door diabetische microangiopathie zijn aangetast. Een derde 
verklaring voor het verhoogde prorenine in plasma zou kunnen zijn dater toegenomen 
productie en secretie is vanuit een extra-renale bran, bijvoorbeeld vanuit de door 
microangiopathie aangetaste vaatwand. Tenslone is het mogelijk dat niet zozeer de 
productie van prorenine maar de eliminatie van prorenine uit de circulatie abnormaal is. 
Het eerste doel van ons onderzoek had betrekking op de vraag of een verhoogd 
plasma prorenine inderdaad een indicator is van diabetische microangiopathie en met 
welke type van complicaties (retinopathie, nephropathie of neuropathie) het verband 
houdt. De mogelijkheid dat verhoogd prorenine verband houdt met veranderingen in het 
koolhydraatmetabolisme bij diabetes werd onderzocht door het hemoglobine Aic en 
bloed glucosete correleren met de prorenine spiegel en doorzowel insuline-afhankelijke 
als niet insuline-afhankelijke patienten te bestuderen. 
De selectieve hyperproreninemie bij diabetes kan samenhangen met een verhoogde 
renale of extra-renale productie van prorenine of met een verminderde klaring of met een 
combinatievan beiden. De mogelijkheid van verhoogde renale productie werd onderzocht 
door de arterioveneuze gradient van prorenine over denier bij patienten met diabetes met 
een hoog prorenine te vergelijken met de gradient bij patienten zonder diabetes mellitus. 
Uit eerder onderzoek van onze groep was duidelijk geworden dat er in he! menselijk 
oog een lokaal renine-angiotensine systeem aanwezig is. In het choroideale weefsel 
konden mRNA's prorenine, angiotensinogeen en ACE worden aangetoond. Omdat een 
verhoogd plasma prorenine duidelijk gecorreleerd bleekte zijn met de aanwezigheid van 
diabetische retinopathie zou het oog een bran van het verhoogde prorenine kunnen zijn. 
Daarom werd bij patienten met proliferatieve retinopathie de invloed van panretinale 
lasercoagulatie op de plasmaspiegel van prorenine bestudeerd. 
8.2 Prorenine in plasma van patienten met en zonder diabetische microvasculaire 
complicaties 
Bij een groep van 223 patienten met diabetes mellitus (hoofdstuk 2) bleek dat de 
plasmaspiegel van prorenine was gecorreleerd zowel met de aanwezigheid van 
nephropathie als met retinopathie, vooral de proliferatieve vorm. 
Retinopathie leek een sterkere determinant te zijn dan nephropathie. lmmers plasma 
prorenine was al verhoogd bij patienten met proliferalieve retinopathie maar met 
albuminurie die nog in het normale gebiedtot30 mg/24h lag. Verder bleekdat in de groep 
met een proteinurievan meerdan 300 mg/24h, maarzonderretinopathie, de plasmaspiegel 
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van prorenine normaal te zijn. De hoogste proreninespiegels werden gevonden bij de 
combinatie van nephropathie en retinopathie. Multiple regressie analyse toonde dat 
leeftijd, duur van de diabetes, geslacht, bloedglucose, HbA 1 c, insulinegebruik, en de 
aanwezigheid van neuropathie geen significante bijdrage leverden tot de correlatie 
tussen prorenine en de aanwezigheid van retinopathie of nephropathie. 
Bij 7 patienten met ernstige gecombineerde nephro- en retinopathie, die een 
nierarteriografre moesten ondergaan in het kadervan een toekomstige niertransplantaf1e, 
vonden wij geen significant verschil tussen prorenine in de niervene en de nierarterie, 
ondanks een sterkverhoogd prorenine gehalte in het perifere plasma en eenverminderde 
nierdoorstroming. Dit maakl het niet waarschijnlijk dat het verhoogde prorenine bij 
diabetes mellitus aileen verklaard zou kunnen worden doortoegenomen renale secretie. 
Bij 16 patienten met een ernstige autonome neuropathie dooreen andere oorzaak dan 
diabetes mellitus, werden geen verhoogde plasma proreninespiegels aangetoond, zodat 
ook autonome diabetische neuropathie niet de verklaring lijkt te zijn voor het verhoogde 
plasma prorenine bij patienten met microvasculaire complicaties. 
8.3 Prorenine in oogvocht van patienten met diabetische retinopathie 
Extra-renale renine-angiotensine systemen worden vooral aangetroffen in vaatrijke 
organen. Anders dan de nier blijken de extra-renale systemen geen renine maar wei 
prorenine af te kunnen geven aan de extracellulaire vloeistof. Prorenine kan mogelijk, 
via intracellulaire conversie tot renine, lei den tot de vorming van angiotensines. Het oog 
is een sterk gevasculariseerd orgaan en retinale vaatnieuwvorming is een belangrijk 
aspect van diabetische retinopathie. Recent onderzoekheeft aangetoond datangiotensine 
II vaatwandgroei kan bevorderen. Angiotensine II applicatie op de cornea van het 
konijne-oog stimuleert vaatnieuwvorming in de cornea. Tevens zijn er angiotensine II 
receptoren aangetoond in de retinale vaten. 
Wij onderzochten de aanwezigheid van de diverse componenten van het renine-
angiotensine systeem in oogvloeistoffen verkregen uit menselijke ogen tijdens 
oogoperaties bij patienten met en zonder diabetes mellitus (hoofdstuk 3). Prorenine was 
aanwezig in kamerwater, glasvocht en subretinaalvocht. 
Het prorenine in glasvocht of subretinaal vocht was vele mal en hager dan op grand van 
het gehalte aan serumeiwitten van deze vochten verwacht kon worden. Bovendien 
bevatte he! glasvocht van patienten met diabetische retinopathie tweemaal zoveel 
prorenine (t.o.v. serumalbumine) als dat van patienten zonder diabetes, terwijl het 
gehalteaan angiotensinogeen (t.o.v. serumalbumine) nietverschilde. Opvallendwasdat 
glasvocht vrijwel geen renine bevatte. Deze bevindingen passen bij locale productie van 
prorenine in het oog. Dit, tezamen met de recente ontdekking van mRNA-expressie van 
renine, angiotensinogeen, en ACE in humaan oogweefsel, duidt op he! bestaan van een 
intra-oculair renine-angiotensine systeem en suggereert een rol van dit intra-oculaire 
systeem bij de ontwikkeling van retinale vaatnieuwvorming bij diabetes mellitus. 
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8.4 Effect van panretinale photocoagulatie op de plasma prorenine spiegel bij patienten 
met diabetische retinopathie. 
Proliferatieve retinopathie is een belangrijke oorzaak van blindheid bij patienten met 
diabetes mellitus. Er zijn aanwijzingen dat retinale hypoxie ten grondslag ligt aan deze 
vaatnieuwvorming en dat de productie van groeifactoren door de ischaemische retina 
hierbij een belanrijke rol speelt. De behandeling van proliferatieve diabetische retinopathie 
bestaat uit panretinale photocoagulatie, welke leidttot regressie van de vaatnieuwvormi ng. 
He! werkingsmechanisme van laserbehandeling is nog niet opgehelderd. Een van de 
veronderstellingen is datlasertherapie de productie van groeifactoren vermindert. 
We onderzochten het effect van laserbehandeling op de plasma prorenine spiegel bij 
12 patienten met onbehandelde proliferatieve retinopathie (hoofdstuk 4). Het idee 
hierachter was dat. als na lasertherapie een daling wordt gevonden van het verhoogde 
plasma prorenine, dit zou pleiten voor productie en afgifte van prorenine naar het bloed 
door het diabetische oog. Hoewel de gemiddelde waarde van prorenine 4 weken na de 
laatste laser behandeling gedaald was, waren de resultaten loch niet eenduidig. Slechts 
bij de helft van de patienten daalde he! plasma prorenine, en het bleef ondanks de daling 
nog steeds verhoogd. Definitieve conclusies omtrent het effect van laserbehandeling op 
de plasma proreninespiegel kunnen dan ook niet getrokken worden. Het kleine aantal 
onderzochte patienten, het ontbreken van een controlegroep en het gebruik van co-
medicatie, die het plasma prorenine kan beinvloeden, kunnen oorzaken zijn van onze 
niet eenduidige resultaten. 
Het is trouwens a priori niet erg waarschijnlijk dat lekkage van prorenine uit het oog 
in belangrijke mate bijdraagttot hetverhoogde plasma prorenine bij patienten met prolife-
ratieve retinopathie. 
Op grand van een lage plasma doorstroming in het oog (0.3mllmin) en een relatief lange 
plasma halfwaardetijd van prorenine (1 tot 2 uur), verwacht men extreem hoge 
proreninespiegels in een of meer oogcompartimenten van het oog. Echter. zulke ex-
treem hoge spiegels zijn nietgemeten in glasvocht van ogen aangedaan doorproliferatieve 
retinopathie. 
8.5 Prorenine in plasma van diabetes patienten met microalbuminurie 
Tot op heden is er geen geschikte (biochemische) plasmamarker voor het ontstaan en 
de ontwikkeling van diabetische microangiopathie bij de diabetes patient. He! bestaan 
van een dergelijke markerzou een belangrijke bijdrage kunnen leverentot het diagnostisch 
en therapeutisch beleid van diabetes patienten. In hoofdstuk 5 beschrijven we bij 164 
diabetes patienten met en zonder microalbuminurie de relatie tussen prorenine en 
microvasculaire complicaties. Deze patienten hadden dus geen macro-albuminurie en 
waren dus voorwat betreft de nephropathie in een vroeg stadium. Plasma prorenine was 
gerelateerd aan de aanwezigheid van zowel retinopathie als microalbuminurie. De mate 
van plasma prorenine verhoging was gerelateerd aan de ernst van zowel retinopathie als 
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nephropathie; de hoogste waarden werden gevonden bij patienten met gecombineerde 
proliferatieve retinopathie en albuminurie. 
Deze cross-sectionele studie wijst op de mogelijkheid dat een verhoogd plasma 
prorenine een vroege marker zou kunnen zijn voor progressieve microangiopathie. 
Microalbuminurie word! doorvele onderzoekers gezien als een indicatorvoorprogressieve 
microvasculaire nephropathie. Microalbuminurie is echter een zeer variabele parameter. 
De albumine excretie via de nier word! beinvloed door vele factoren, zoals houding, 
inspanning, dieet, metabole regulatie en arteriele bloeddruk. 
Bij een groep van 72 patienten met insuline-afhankelijke diabetes mellitus werden 
prorenine en de albumine uitscheiding op drie verschillende tijdstippen binnen een 
peri ode van 4 weken bepaald. De variatiecoefficient van de prorenine uitslagen bedroeg 
9% tegenover35% voorde albuminurie uitkomsten. Bepalingen van prorenine geven dus 
veel minder variabele resultaten dan bepalingen van de microalbuminurie. 
De sensitiviteit en specificiteit van een plasma prorenine bepaling, in een groep van 140 
patienten met insuline afhankelijke diabetes mellitus, als diagnostische test voor de 
aanwezigheid van albuminurie waren resp. 0.72 en 0.72. De sensitiviteit en specificiteit 
voor het aantonen van retinopathie en/of albuminurie was 0.60 en 0.89. 
Een verhoogd plasma prorenine is dus zeker geen gevoelige indicatorvoorde aanwezig-
heid van microangiopathie. Misschien dat plasma prorenine wei gebnuikt kan worden 
voor de follow-up van microvasculaire complicaties. Longitudinaal onderzoek dient 
daarom onze cross-sectionele gegevens aan te vullen. 
Hetis onbekend ofdeverhogingvan het plasma prorenine in eenvroeg ollaatstadium 
van de microvasculaire complicaties optreedt Er zijn aanwijzingen dat een verhoging 
van he! plasma prorenine reeds kan optreden voordat de eerste tekenen van 
microvasculaire complicaties klinisch manifest worden. 
Bij een groep van 25 normotensieve patienten met insuline- alhankelijke diabetes 
mellitus en een slechts Iicht verhoogde albumine uitscheiding via denier onderzochten 
wij prospectief gedurende 2 jaar de plasma prorenine concentraties en de progressie van 
albuminurie (hoofdstuk 6). Progressie van albuminurie was niet gerelateerd aan de 
plasma prorenine waarde en plasma prorenine veranderde niet tijdens de follow-up 
peri ode. 
Progressie van albuminurie was gerelateerd aan de bloeddruk (ook al was deze niet 
verhoogd volgens de WHO criteria) en aan de aanwezigheid van retinopathie. Retinopathie 
leek een sterkere detenminant voorverhoogd plasma proreninete zijn dan microalbuminurie. 
Deze gegevens ondersteunen niet de hypothese dat een vroege toename van 
microalbuminurie door plasma prorenine bepalingen opgespoord zou kunnen worden. 
Het is mogelijk dat pas bij een hogere albumine excretie een stijging van plasma 
prorenine optreedt of dat een verhoogd plasma prorenine geassocieerd is met bepaalde 
aspecten van microangiopathie die geen verband kenden met het ontstaan van 
microalbuminurie. 
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8.6 Therapeutische implicaties 
Studies met geneesmiddelen die ingrijpen in het RAS syteem zoals de ACE-remmers 
tonen bij patienten met type I diabetes mellitus en nephropathie een reductie van de 
albuminurie, zelfs bij normotensieve patienten (1-4). 
Er zijn aanwijzingen dat behandeling met ACE-remmers de progressie van diabetische 
nephropathie, deels onafhankelijk van het effect op de bloeddruk, vertraagt (5-7). 
Ons onderzoek toont duidelijke aanwijzingen voor het bestaan van een intra-oculair 
renine-angiotensine systeem en suggereert een rol voor dit systeem bij het ontstaan van 
diabetische retinopathie. Het zou kunnen zijn dat een verhoogd plasma prorenine een 
uiting is van een gestimuleerd locaal renine-angiotensine systeem in weefsels waarin de 
microvasculaire afwijkingen zich ontwikkelen. 
Geneesmiddelen die ingrijpen in dit systeem, zoals ACE-remmers, specifieke renine-
remmers en Angiotensine II antagonisten, hebben misschien een therapeutisch effect 
bij diabetische retinopathie. Parving et al (8) toonden recentelijk aan dat een ACE-
remmer de eiwitlekkage vanuit de retinale vaten in ogen met achtergrondsretinopathie 
verminderde. Studies gericht op het effect van ACE-remmers op het ontstaan en de 
progressie van retinale neovascularisatie bij patienten met diabetes mellitus, zijn dan 
ook zeker aangewezen. 
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